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BACKGROUND. The American Cancer Society, Centers for Disease Control and Pre-
vention, National Cancer Institute, and North American Association of Central
Cancer Registries collaborate annually to provide U.S. cancer information, this
year featuring the first comprehensive compilation of cancer information for U.S.
Latinos.
METHODS. Cancer incidence was obtained from 90% of the Hispanic/Latino and
82% of the U.S. populations. Cancer deaths were obtained for the entire U.S. popu-
lation. Cancer screening, risk factor, incidence, and mortality data were compiled
for Latino and non-Latino adults and children (incidence only). Long-term (1975–
2003) and fixed-interval (1995–2003) trends and comparative analyses by disease
stage, urbanicity, and area poverty were evaluated.
RESULTS. The long-term trend in overall cancer death rates, declining since the
early 1990s, continued through 2003 for all races and both sexes combined. How-
ever, female lung cancer incidence rates increased from 1975 to 2003, decelerating
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since 1991 and breast cancer incidence rates stabilized from 2001 to 2003. Latinos had
lower incidence rates in 1999–2003 for most cancers, but higher rates for stomach, liver,
cervix, and myeloma (females) than did non-Latino white populations. Latino children
have higher incidence of leukemia, retinoblastoma, osteosarcoma, and germ-cell tumors
than do non-Latino white children. For several common cancers, Latinos were less likely
than non-Latinos to be diagnosed at localized stages.
CONCLUSIONS. The lower cancer rates observed in Latino immigrants could be sustained
by maintenance of healthy behaviors. Some infection-related cancers in Latinos could be
controlled by evidence-based interventions. Affordable, culturally sensitive, linguistically
appropriate, and timely access to cancer information, prevention, screening, and treat-
ment are important in Latino outreach and community networks. Cancer 2006;107:
1711–42. Published 2006 by the American Cancer Society.*
KEYWORDS: cancer, incidence, mortality, Hispanic, Latino, NAACCR, SEER, NPCR, vital
statistics, United States, health disparity, cancer inequality.
T he American Cancer Society (ACS), the Centers forDisease Control and Prevention (CDC), the National
Cancer Institute (NCI), and the North American Asso-
ciation of Central Cancer Registries (NAACCR) collabo-
rate annually to assess the status of cancer in the
United States (U.S.). The 1998 report documented the
first sustained decline in cancer death rates since the
1930s. Subsequent reports updated information on
trends in incidence and death rates and featured timely
topics.1–8 This report continues the annual update tra-
dition and presents a special section on cancer among
U.S. Hispanic/Latino populations, a large and diverse
ethnic group whose cancer experience has not been
well described until recently9,10 as concerns about mis-
classification and cultural and other differences among
various Latino groups and limited population data have
restricted national analyses. Although challenges re-
main, a comprehensive compilation of cancer infor-
mation for the estimated 39.9 million U.S. Latinos in
2003 is relevant to future directions in cancer control
strategies.11
MATERIALS AND METHODS
Data Sources for Cancer Cases and Deaths
U.S. state and regional population-based cancer regis-
tries collect information on new cancer diagnoses. They
participate in the NCI’s Surveillance, Epidemiology, and
End Results (SEER) Program, the CDC’s National Pro-
gram of Cancer Registries (NPCR), or both. All cancer
registries are members of NAACCR. Incidence data refer
to invasive cancers, excluding in situ, with the exception
of bladder. Primary cancer site and histology data were
coded according to the International Classification of
Diseases for Oncology (ICD-O) edition in use at the
time of diagnosis, converted to the Third Edition,12 and
categorized according to SEER site groups (To maxi-
mize comparability between ICD-O-2 and ICD-O-3,
borderline tumors of the ovary, refractory anemias,
and other myelodysplastic syndromes were excluded,
and pilocytic astrocytomas were included.).13 For per-
sons aged 0–19 years, cancer data were categorized
using the International Classification of Childhood
Cancer (ICCC) based on ICD-O-3.12,14 Statistics for
men and women include persons of all ages; childhood
cancers include persons aged 0–14 years, and adoles-
cents aged 15–19 years.
U.S. cancer deaths, reported to state vital statistics
offices and consolidated through the CDC’s National
Vital Statistics System,15 were coded using the version
of the International Classification of Diseases (ICD) in
use at the time of death.16–19 Underlying causes of can-
cer death for the total U.S. were grouped for maximum
comparability among ICD versions.13 Mortality data
are provided by all 50 states and the District of Colum-
bia; however, death rates for Hispanics from 5 states
(Maine, Minnesota, New Hampshire, North Dakota,
and Oklahoma) were excluded because of incomplete
ethnicity information for at least one of the reporting
years in the report.20
All analyses (long-term trends, fixed interval trends,
and average annual rates) were based on national mor-
tality data and varying geographic areas for incidence
because incidence data are not uniformly available for
all population groups, time periods, and geographic
areas. (We examined data for 22 sites for incidence
and 21 for cancer deaths to accommodate the top 15
cancers in each racial and ethnic population. Kaposi
Sarcoma and mesothelioma were only reported as
cause of death beginning in 1999 and therefore not
reported separately for mortality.) Long-term (1975–
2003) trends for all races combined by sex for all-sites
combined and the 15 most common cancers were
based on SEER incidence data covering about 10%
of the U.S. population, the only source for long-term
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incidence analyses.21 Fixed-interval trends (1995 through
2003) for 6 race/ethnic populations (white, black, Amer-
ican Indian/Alaska Native (AI/AN), and Asian Pacific
Islander (API) race groups and Hispanic/Latino and
non-Hispanic ethnic groups regardless of race), by sex,
for all sites combined and the 15most common cancers
were based on 73% of the U.S. population. Data for AI/
AN are not presented, despite recent linkages of registry
data with the Indian Health Service patient database to
improve identification, because the linkage variable
was not available at the time of analysis. Average-
annual (covering the 5-year period with the sum of all
annual cases divided by the total annual population
estimates for the same time interval) (1999–2003), sex-
specific, and age-adjusted incidence rates were based
on incidence data from 38 cancer registries, covering
about 82% of the U.S. population, including 90% of the
U.S. Latinos. All registries included in the analyses met
NAACCR’s standard for high quality cancer incidence
data. Analyses on stage of disease excluded data from
Maryland because of incomplete data, and analyses on
county measures excluded data from Hawaii because a
county identifier was not available on the file. Table 1
summarizes the descriptions of the cancer incidence
data sets used for the various analyses.
Cancer incidence and death information is not
shown for specific API and Hispanic/Latino groups be-
cause identifiers for these groups are not universally
complete on reports of cases and deaths and intercen-
sal county population estimates are not available from
the U.S. Census Bureau.
Risk Factors and Screening
Data on socioeconomic status (SES), behavioral risk
factors, and cancer screening by race, ethnicity, and
Mexican, Puerto Rican, and Cuban groups, were ob-
tained from the U.S. Census Bureau and the 2003
National Health Interview Survey (NHIS),22,23 categor-
ized according to Healthy People 2010 objectives. (In
the 2003 NHIS,74% of eligible adults responded. Black
and Hispanic/Latino persons were oversampled in
the survey, and among Latinos, 63% self-identified as
Mexican or Mexican American, 10% as Puerto Rican,
5% as Cuban or Cuban American, 3% as Dominican,
18% as another Hispanic descent, and 1% with multiple
Hispanic origins.)24 Cigarette smoking, physical activity,
alcohol consumption, and Pap tests (women only) were
asked of adults aged 18 years or older. Also asked were
mammography among women aged 40 years or older,
colorectal cancer screening among persons aged
50 years or older, and prostate specific antigen (PSA)
testing among men aged 50 and older who reported no
history of prostate cancer. Self-reported obesity preva-
lence was estimated among adults aged 20 years and
older, as were measured obesity estimates25 from the
National Health and Nutrition Examination Survey.26
To describe the variation in cancer incidence by a
geographic area’s socioeconomic climate, we used the
percent of county residents who lived below the poverty
level.27–32 County poverty rates are a composite eco-
nomic characteristic of a geographic area, including a
reflection of health care services.28–31 County-level pov-
erty data for all races combined were categorized into 3
TABLE 1
Summary Description for Data Sets Used in Cancer Incidence Analyses
Trends
Incidence &
Incidence
Statistical measure Long-term Fixed interval rate ratios Rates
Data source SEER9 30 states 38 states 37 states* 37 statesy 36 states*,y
Time period 1975–2003 1995–2003 1999–2003 1999–2003 2001–2003 2001–2003
% Population coverage
Total 10 73 82 82 80 80
Hispanic 88 90 90 89 89
NH 70 81
White
NHW 81 81 79 79
All 73 82
Black
NHB 79 79 75 75
All 65 80
All API 88 92
* Analyses using county identifiers exclude Hawaii.
y Analyses of disease stage exclude Maryland.
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groups according to the percent of the county popula-
tion below the poverty level in 1999: <10%, 10%–19%,
and 20% (most economically disadvantaged).27,30
Cancer incidence rate variations betweenmetropol-
itan (metro) and nonmetropolitan (nonmetro) counties
were assessed using the 2003 Urban/Rural Contin-
uum,33 also consistent with the Office of Management
and Budget metro categories. This U.S. schema in-
cludes 813 metro counties (continuum codes 0 through
3) and 2288 nonmetro counties (codes 4 through 9).33
We examined the distribution of stage of disease at di-
agnosis for cancers of the breast, prostate, colon and rec-
tum, lung, and cervix by county poverty groups. Cancer
incident cases were staged using the 2000 SEER summary
staging system. To eliminate the effect of a different sta-
ging system in use before 2001, only cases diagnosed from
2001 to 2003were selected for cancer stage statistics.34
Hispanic/Latino Ethnicity Definition
Self-report provides the best and most direct ap-
proach to identify a person’s race; however, this infor-
mation is not always available on cancer records.
NAACCR developed a standard approach to improve
the identification of Latino ethnicity for cancer cases
and it was used for this report. The NAACCR Hispanic/
Latino Identification Algorithm, version 2 (NHIA v2),
includes both direct and indirect identification of
Latino cases, resulting in all persons having an ethnic-
ity assigned. The indirect component is a hierarchical
algorithm of ethnicity assignment based on race, birth-
place, gender, maiden name, and surname.35
The termsHispanic, Latino, or Latina, are used to refer
to persons of Hispanic origin. The word Hispanic is a U.S.
federal designation, used in national and state reporting
systems. Latino/a is a self-designated term of ethnicity. To
be parsimonious in the text and tables, the terms Latino,
Hispanic, non-Hispanic white (NHW), and non-Hispanic
black (NHB) are usedwithout preference or prejudice.
Statistical Analysis
Cancer incidence and death rates are expressed for
1999–2003 per 100,000 persons and age-adjusted by
19 age groups (<1, 1–4, 5–9, . . . , 80–84, 85þ) to the
2000 U.S. standard population.13,36 (The NCHS pub-
lishes age-adjusted death rates using the established
federal methodology based on 11 age groups, typically
in 10-year age categories [<1, 1–4, 5–14, 15–24, . . . ,
65–74, 75–84, 85þ] and weights from the 2000 popula-
tion projections.36 The number of age groups [e.g.,
single-year, 5-year, or 10-year] used for age adjustment
may affect estimated rates slightly.21) Cancer incidence
rates for 0–19 year olds are expressed per million per-
sons and age-adjusted within the same age categories
noted earlier. Age-adjustment eliminates the age effect
on statistics, facilitating comparisons of other variables
of interest (e.g., ethnicity). Rates, standard errors,37 and
95% confidence intervals (95% CI) were generated using
SEER*Stat Software (www.seer.cancer.gov/seerstat/).
Long-term cancer incidence and death trends (1975
through 2003) are described using joinpoint analysis for
all races combined.38 Statistical significance was set at
P < .05. We present the observed incidence trends and
those adjusted for reporting delay (mostly affecting re-
cent years) using models based on long-term reporting
patterns in SEER.39 Descriptions of long-term cancer
incidence trends are based on the delay-adjusted rates.
Annual percent change analysis (not delay-adjusted)
was used to describe fixed interval trends (1995–2003).
For all trends, the term increase or decrease (negative sign)
was used when the slope of the trend was statistically sig-
nificant; otherwise, the term stable or level was used.
Prevalence estimates for screening and risk factors
were calculated using data from the 2003 NHIS sample
adult file and age-adjusted to the 2000 U.S. standard
population and sample-weighted using SUDAAN soft-
ware to account for the complex NHIS sampling
design.40,41 This followed standard procedures for ana-
lyzing NHIS data. (A table of 95% CI is available at:
www.seer.cancer.gov/report_to_nation/1975_2003/).
Data were suppressed when cell counts were less
than 50 persons following NHIS rules.
Incidence rate comparisons by county poverty,
metro area, and disease stage among Hispanic, NHW,
and NHB populations are shown by rate ratios (RR),
with Hispanics/Latinos compared with NHW and NHB
groups. A 95% CI is presented for RRs to show preci-
sion, in addition to stating statistical significance (P <
.05) of comparisons. In describing all comparisons, the
terms higher (more likely) or lower (less likely) were
used when the difference in the rates was statistically
significant (P <.05). Otherwise, the RRs were described
as comparable. Thus, when the RR was less than 1.0,
the rate among Latinos was lower, and if greater than
1.0 the rate was higher, than the comparison group.
Since population estimates for specific Latino
population groups are not available from the US Bureau
of the Census by age and sex for all years (1999–2003),
the proportional incidence ratio (PIR) was used to com-
pare the proportion of all cancer cases due to a specific
cancer type among a specific Latino group with the cor-
responding proportion among NHW persons. The PIR
uses age-adjustment analogous to indirect age stan-
dardization whereby the proportions are dependent on
other cancer types. The 95% CI is presented to reflect
the precision of the PIR estimate.42
More information related to this report is avail-
able at the NCI Web site www.seer.cancer.gov/report_
to_nation/1975_2003/. Additional cancer data are
available from www.cancer.org (ACS); www.cdc.gov/
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TABLE 2
SEER Incidence Rate Trends with Joinpointa Analyses for 1975 through 2003 for the Top 15 Cancers,b All Races
Joinpoint analyses (1975–2003)c
Trend 1 Trend 2 Trend 3 Trend 4
Years APCd Years APCd Years APCd Years APCd
All Sitese
Both Sexes 1975–1992 1.4f 1992–2003 0.4f
(Delay-adjusted) 1975–1983 0.9f 1983–1992 1.8f 1992–1995 1.5 1995–2003 0.1
Male 1975–1989 1.3f 1989–1992 5.0f 1992–1995 4.4f 1995–2003 0.3
(Delay-adjusted) 1975–1989 1.3f 1989–1992 5.1f 1992–1995 4.5f 1995–2003 0.0
Female 1975–1979 0.2 1979–1987 1.5f 1987–2001 0.3f 2001–2003 2.3
(Delay-adjusted) 1975–1979 0.3 1979–1987 1.6f 1987–2003 0.3f
Top 15 for male
Prostate 1975–1988 2.6f 1988–1992 16.3f 1992–1995 10.7f 1995–2003 0.7
(Delay-adjusted) 1975–1988 2.6f 1988–1992 16.4f 1992–1995 10.8f 1995–2003 1.1f
Lung and Bronchus 1975–1982 1.5f 1982–1991 0.5f 1991–2003 1.8f
(Delay-adjusted) 1975–1982 1.5f 1982–1991 0.5f 1991–2003 1.7f
Colon and Rectum 1975–1986 1.1f 1986–1995 2.1f 1995–1998 1.1 1998–2003 2.8f
(Delay-adjusted) 1975–1986 1.1f 1986–1995 2.1f 1995–1998 1.0 1998–2003 2.5f
Urinary Bladder 1975–1987 1.0f 1987–1996 0.5 1996–2000 1.5 2000–2003 2.3f
(Delay-adjusted) 1975–1987 1.0f 1987–1995 0.6 1995–2000 1.2 2000–2003 1.5
Non-Hodgkin Lymphoma 1975–1991 4.3f 1991–2003 0.0
(Delay-adjusted) 1975–1991 4.3f 1991–2003 0.2
Melanoma of the Skin 1975–1985 5.5f 1985–2001 3.3f 2001–2003 3.3
(Delay-adjusted) 1975–1985 5.5f 1985–2001 3.4f 2001–2003 0.9
Kidney and Renal Pelvis 1975–2003 1.7f
(Delay-adjusted) 1975–2003 1.8f
Leukemia 1975–2001 0.1 2001–2003 4.4
(Delay-adjusted) 1975–2003 0.2f
Oral Cavity and Pharynx 1975–1983 0.1 1983–2003 1.5f
(Delay-adjusted) 1975–2003 1.2f
Pancreas 1975–1981 1.8f 1981–1985 1.2 1985–1989 2.5 1989–2003 0.1
(Delay-adjusted) 1975–1981 1.8f 1981–1985 1.1 1985–1990 2.1f 1990–2003 0.1
Stomach 1975–1988 1.2f 1988–2003 2.1f
(Delay-adjusted) 1975–1988 1.2f 1988–2003 2.1f
Liver and Intrahepatic Bile Duct 1975–1984 1.7 1984–1998 4.5f 1998–2003 0.9
(Delay-adjusted) 1975–1986 2.1f 1986–1996 5.1f 1996–2003 2.4f
Brain and Other Nervous System 1975–1991 1.0f 1991–2003 0.7f
(Delay-adjusted) 1975–1989 1.2f 1989–2003 0.4
Esophagus 1975–2003 0.7f
(Delay-adjusted) 1975–2003 0.7f
Myeloma 1975–2003 0.7f
(Delay-adjusted) 1975–2003 0.9f
Top 15 for female
Breast 1975–1980 0.4 1980–1987 3.7f 1987–2001 0.4f 2001–2003 4.8
(Delay-adjusted) 1975–1980 0.4 1980–1987 3.7f 1987–2001 0.5f 2001–2003 4.1
Lung and Bronchus 1975–1982 5.5f 1982–1990 3.5f 1990–1998 1.0f 1998–2003 0.5
(Delay-adjusted) 1975–1982 5.6f 1982–1991 3.4f 1991–2003 0.5f
Colon and Rectum 1975–1985 0.3 1985–1995 1.9f 1995–1998 1.7 1998–2003 2.2f
(Delay-adjusted) 1975–1985 0.3 1985–1995 1.8f 1995–1998 1.7 1998–2003 1.9f
Corpus and Uterus, NOS 1975–1979 6.0f 1979–1988 1.7f 1988–1998 0.6f 1998–2003 1.2f
(Delay-adjusted) 1975–1979 6.0f 1979–1988 1.7f 1988–1998 0.7f 1998–2003 1.0f
Non-Hodgkin Lymphoma 1975–1990 2.9f 1990–2003 1.0f
(Delay-adjusted) 1975–1990 2.8f 1990–2003 1.3f
Melanoma of the Skin 1975–1981 5.2f 1981–2003 2.2f
(Delay-adjusted) 1975–1981 4.9f 1981–2003 2.4f
Ovarye 1975–1987 0.1 1987–2003 0.9f
(Delay-adjusted) 1975–1985 0.2 1985–2003 0.7f
Thyroid 1975–1977 6.6 1977–1980 5.3 1980–1995 2.3f 1995–2003 5.9f
(Delay-adjusted) 1975–1981 1.3 1981–1993 2.2f 1993–2000 4.6f 2000–2003 9.1f
(continued )
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cancer/npcr/index.htm and www.cdc.gov/nchs/about/
major/dvs/mortdata.htm (CDC); www.naaccr.org/CINAP/
index.htm (NAACCR); and www.seer.cancer.gov (SEER).
RESULTS
Update on Long-term Incidence Trends for All Cancers
Combined and the 15 Most Common Cancer Sites
for All Races, 1975--2003
Age-adjusted cancer incidence rates for all sites, sexes,
and populations combined increased from 1975 to 1983,
increased at an accelerated rate from 1983 to 1992, and
have been stable from 1992 through 2003 (Table 2). For
men, incidence rates for all cancers combined increased
from 1975 to 1989, increased at a faster rate from 1989 to
1992, decreased from 1992 to 1995, and were stable from
1995 through 2003. For women, incidence rates for all
cancers combined increased from 1979 through 2003.
Among men, prostate cancer incidence increased
from 1995 through 2003 (Table 2). The incidence rates
for myeloma and leukemia, and cancers of the liver
and intrahepatic bile duct (liver), kidney and renal pel-
vis (kidney), and esophagus have been increasing for
28 years (from 1975 through 2003). Incidence rates
decreased for colon and rectum cancer during 1998–
2003, while cancer incidence rates of the stomach and
oral cavity and pharynx (oral cavity) have decreased
since 1975 and those of lung and bronchus (lung) since
1982. Incidence rates were stable in the most recent
joinpoint segment through 2003 for the remaining top
15 cancer sites (urinary bladder [bladder], non-Hodgkin
lymphoma [NHL], melanoma of the skin [melanoma],
and cancers of the pancreas and brain and other ner-
vous system [brain]). Cancer of the larynx, on the top
15 sites for males in previous years, was replaced by
myeloma in this year’s ranking.
Among women, the rates for NHL, melanoma, leuke-
mia, and cancers of the lung, bladder, and kidney have
been increasing for 28 years. The cancer incidence rates
decreased during the most recent segment for cancers of
the colon and rectum, corpus and uterus NOS (uterine
corpus), ovary, and oral cavity, while stomach and cervix
uteri (cervix) cancers have declined since 1975. The inci-
dence rates for breast cancer stabilized from 2001
through 2003, ending increases begun in the 1980s. The
incidence rates for pancreatic cancer also stabilized from
2000 through 2003, after decreasing for 16 years.
In women, thyroid cancer incidence rates have
increased since 1981; the rate of increase doubling in
1993; and in 2000, doubling again to 9.1% annually
through 2003. The long-term rates increased in all age
groups in both men and women, although the most
dramatic increase in men occurred since 1996 among
TABLE 2
(continued )
Joinpoint analyses (1975–2003)c
Trend 1 Trend 2 Trend 3 Trend 4
Years APCd Years APCd Years APCd Years APCd
Pancreas 1975–1983 1.4f 1983–2003 0.2
(Delay-adjusted) 1975–1984 1.3f 1984–2000 0.3f 2000–2003 2.7
Leukemia 1975–2001 0.0 2001–2003 5.0
(Delay-adjusted) 1975–2003 0.2f
Urinary Bladder 1975–2003 0.2f
(Delay-adjusted) 1975–2003 0.2f
Cervix Uteri 1975–1981 4.5f 1981–1997 1.2f 1997–2003 4.5f
(Delay-adjusted) 1975–1981 4.6f 1981–1997 1.1f 1997–2003 4.3f
Kidney and Renal Pelvis 1975–2003 2.2f
(Delay-adjusted) 1975–2003 2.3f
Oral Cavity and Pharynx 1975–1980 2.7 1980–2003 1.0f
(Delay-adjusted) 1975–1980 2.5 1980–2003 0.9f
Stomach 1975–2003 1.7f
(Delay-adjusted) 1975–2003 1.6f
Source: SEER 9 areas covering about 10% of the U.S. population (Connecticut, Hawaii, Iowa, Utah, and New Mexico, and the metropolitan areas of San Francisco, Detroit, Atlanta, and Seattle-Puget Sound).
APC: annual percent change; NOS: not otherwise specified.
a Joinpoint (JP) Regression Program, Version 3.1. April 2006, National Cancer Institute.
b The top 15 cancers were selected based on the sex-specific age-adjusted rate for 1999–2003 for all races combined and listed in rank order.
c Joinpoint analyses with up to 3 joinpoints are based on rates per 100,000 age-adjusted to the 2000 US Std Population (19 age groups - Census p25-1130).
d APC ¼ annual percent change based on rates that were age-adjusted to the 2000 US Std Population (19 age groups - Census p25-1130) using joinpoint regression analysis.
e All sites excludes myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.
f APC is statistically different from zero (two-sided P < .05).
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60–69 year olds (age-specific and long-term trends in
males not shown).
Update on Long-term Mortality Trends for All Cancers
Combined and the 15 Most Common Cancer Sites for
All Races, 1975--2003
The overall cancer death rates for all race/ethnic
populations together increased from 1975 to 1990,
were stable from 1990 to 1994, and decreased from
1994 through 2003. The most recent rate declines
were greater among men (1.6% per year from 1993
through 2003) than women (0.8% per year from 1992
through 2003) (Table 3).
In the most recent joinpoint segment, death rates
decreased for 11 of the 15 most common cancers in men
(i.e., lung, prostate, colon and rectum, pancreas, leuke-
TABLE 3
US Death Rate Trends with Joinpointa Analyses for 1975 through 2003 for the Top 15 Cancers,b All Races
Joinpoint analyses (1975–2003)c
Trend 1 Trend 2 Trend 3 Trend 4
Years APCd Years APCd Years APCd Years APCd
All Sites
Both Sexes 1975–1990 0.5e 1990–1994 0.4 1994–2003 1.1e
Male 1975–1979 1.0e 1979–1990 0.3e 1990–1993 0.4 1993–2003 1.6e
Female 1975–1992 0.5e 1992–2003 0.8e
Top 15 for male
Lung and Bronchus 1975–1978 2.4e 1978–1984 1.2e 1984–1991 0.3e 1991–2003 1.9e
Prostate 1975–1987 0.9e 1987–1991 3.1e 1991–1994 0.6 1994–2003 4.0e
Colon and Rectum 1975–1978 0.8 1978–1984 0.4 1984–1990 1.3e 1990–2003 2.1e
Pancreas 1975–1986 0.8e 1986–2003 0.3e
Leukemia 1975–1995 0.2e 1995–2003 0.7e
Non-Hodgkin Lymphoma 1975–1981 1.8e 1981–1990 3.0e 1990–1997 1.6e 1997–2003 2.8e
Esophagus 1975–1985 0.7e 1985–1994 1.2e 1994–2003 0.5e
Urinary Bladder 1975–1983 1.4e 1983–1987 2.8e 1987–1993 0.1 1993–2003 0.7e
Liver and Intrahepatic Bile Duct 1975–1985 1.5e 1985–1995 3.8e 1995–2003 1.8e
Stomach 1975–1987 2.3e 1987–1991 0.9 1991–2003 3.5e
Kidney and Renal Pelvis 1975–1991 1.1e 1991–2003 0.1
Brain and Other Nervous System 1975–1977 4.4 1977–1982 0.5 1982–1990 1.5e 1990–2003 0.8e
Myeloma 1975–1994 1.5e 1994–2003 0.9e
Oral Cavity and Pharynx 1975–1980 0.8 1980–2003 2.3e
Melanoma of the Skin 1975–1991 2.1e 1991–2003 0.1
Top 15 for female
Lung and Bronchus 1975–1982 6.0e 1982–1990 4.2e 1990–1995 1.7e 1995–2003 0.3e
Breast 1975–1990 0.4e 1990–1995 1.8e 1995–1999 3.1e 1999–2003 1.4e
Colon and Rectum 1975–1984 1.0e 1984–2003 1.9e
Pancreas 1975–1984 0.8e 1984–2003 0.1
Ovary 1975–1982 1.2e 1982–1992 0.3 1992–1998 1.1e 1998–2003 0.4
Non-Hodgkin Lymphoma 1975–1995 2.2e 1995–1998 0.3 1998–2003 3.7e
Leukemia 1975–1980 0.9 1980–2003 0.5e
Corpus and Uterus, NOS 1975–1991 1.6e 1991–2003 0.1
Brain and Other Nervous System 1975–1992 0.9e 1992–2003 1.0e
Myeloma 1975–1993 1.5e 1993–2003 0.6e
Stomach 1975–1987 2.8e 1987–1990 0.5 1990–2003 2.6e
Liver and Intrahepatic Bile Duct 1975–1981 0.1 1981–1988 1.7e 1988–1995 3.7e 1995–2003 0.7e
Kidney and Renal Pelvis 1975–1992 1.3e 1992–2003 0.5e
Cervix Uteri 1975–1982 4.3e 1982–1996 1.6e 1996–2003 3.8e
Urinary Bladder 1975–1986 1.7e 1986–2003 0.4e
Source: National Center for Health Statistics public-use data file for the total U.S.
APC: annual percent change; NOS: not otherwise specified.
a Joinpoint (JP) Regression Program, Version 3.1. April 2006, National Cancer Institute.
b The top 15 cancers were selected based on the sex-specific age-adjusted rate for 1999–2003 for all races combined and listed in rank order.
c Joinpoint analyses with up to 3 joinpoints are based on rates per 100,000 age-adjusted to the 2000 US Std Population (19 age groups - Census p25-1130).
d APC ¼ Annual percent change based on rates that were age-adjusted to the 2000 US Std Population (19 age groups - Census p25-1130) using joinpoint regression analysis.
e APC is statistically significantly different from zero (two-sided P < .05).
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mia, NHL, bladder, stomach, brain, myeloma, and oral
cavity) and for 10 of the 15 most common cancers in
women (i.e., breast, colon and rectum, NHL, leukemia,
brain, myeloma, stomach, kidney, cervix, and bladder).
Further, sustained decreases since 1975 have occurred in
men for pancreatic cancer and leukemia, and among
women, cancers of the colon and rectum, cervix, and
bladder. Death rates increased for esophageal cancer
from 1975 through 2003 in men, and for liver cancer at
varying rates from 1975 through 2003 in men and 1981
through 2003 in women. Lung cancer increased from
1975 through 2003 in women; however, the rate of
increase decelerated over time. Death rates were stable in
men for kidney cancer and melanoma (both 1991–2003),
and in women, for cancers of the pancreas (1984–2003),
ovary (1998–2003), and uterine corpus (1991–2003).
Cancer Incidence and Death Rates, 1999–2003, and
Fixed Interval Trends, 1995–2003
Among men, the top 3 incident cancers from 1999
through 2003 continued to be cancers of the prostate,
lung, and colon and rectum in all race/ethnic popula-
tions (Table 4). Bladder cancer and NHL were the
fourth and fifth most common cancers in most race/
ethnic populations, with the exception of black and
API men. Cancers of the kidney and bladder were the
fourth and fifth most common sites in black men,
and in API men, they were cancers of the liver and
stomach. Incidence rates declined from 1995 through
2003 for cancers of the lung, stomach, oral cavity, and
larynx and increased for thyroid cancer in all race/
ethnic populations examined. Incidence rates of kid-
ney and liver cancers increased in all race/ethnic
populations except API. Colon and rectum cancer
incidence rates declined in white and non-Hispanic
(all races) men, but not in others. NHL incidence
rates declined in all race/ethnic populations, except
non-Hispanic and API. Incidence rates were stable for
cancers of the prostate and bladder in all race/ethnic
populations. Three of the top 15 common cancers had
different 1995–2003 trends among the race/ethnic groups.
Pancreatic cancer incidence rates increased in white
and non-Hispanic men, but decreased in black men;
esophageal cancer incidence rates decreased in Latino
(all races), black, and API, but increased in white and
non-Hispanic, men. Melanoma increased in non-
Hispanic and white men, but decreased in black men.
Among women, cancers of the breast, colon and
rectum, lung, and uterine corpus continued to be the
top 4 incident cancers from 1999 through 2003 in all
race/ethnic populations, although the rank order of
the top 3 cancers varied (Table 4). The fifth most
common cancer was NHL in women of all races and
ethnicities, except black and API women. The fifth
most common cancer was pancreas in black, and
thyroid in API, women. Cervical cancer was the only
cancer among the top 15 cancers that decreased in
women of all races and ethnicities, while cancers of
the kidney and thyroid were the only cancers that in-
creased in all female populations. Lung cancer inci-
dence rates continued to increase from 1995 through
2003 in non-Hispanic (all races) and white women, but
not in women of other races or ethnicity. Incidence
rates were stable for cancers of the breast and colon
and rectum in all race/ethnic populations, except co-
lon and rectal cancer in white women, for which the
rates declined from 1995 through 2003. Melanoma in-
creased in non-Hispanic, white, and API women. Inci-
dence rates of NHL increased in non-Hispanic and
black women, but not in others. Ovarian cancer inci-
dence rates declined in women of most races and eth-
nicity, except black and API women. Stomach cancer
incidence rates decreased in women of all races and
ethnicities, except Latinas.
The fixed-interval incidence trends from 1995 to
2003 showed more sex than racial/ethnic differences.
The trends in more of the top 15 cancer sites in men
were decreasing for each population group than among
the top 15 cancer sites in women.
Among men, the 3 leading causes of cancer death
from 1999 to 2003 continued to be cancers of the lung,
prostate, and colon and rectum in most race/ethnic
populations (Table 5), except API males, in whom they
were lung, liver, and colon and rectum. Trends in death
rates declined from 1995 through 2003 for cancers of
the lung, prostate, and colon and rectum in all race/
ethnic populations, except API and AI/AN, in whom
death rates were stable for cancer of the colon and rec-
tum. Death trends for cancers other than the 3 leading
cancers varied by racial/ethnic population. Death rates
of liver cancer increased from 1995 through 2003 in
Latino, non-Latino, and white men and were stable in
black, API, and AI/AN men. Death rates of esophageal
cancer declined in Hispanic and black men, increased
in non-Hispanic and white men, and were stable in
API and AI/AN men. Death rates declined from 1995
through 2003 in 11 of 16 cancers in non-Latinos and 9
of 16 cancers in Latinos. Differences were observed for
cancers of the bladder and brain, leukemia, and my-
eloma, where rates in Latinos were stable; melanoma,
where rates in Latinos decreased; and esophageal can-
cer where rates in Latinos decreased and those in
white men increased.
Among women, cancers of the breast, lung, and
colon and rectum continued to be the 3 leading causes
of cancer death from 1999 to 2003 in all racial and eth-
nic populations, although the rank of the second and
third cancers varied (Table 5). Compared with men,
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TABLE 4
Age-Adjusted Incidence Rates for 1999–2003 and Fixed Interval Trends for 1995–2003 for the Top 15 Cancersa by Sex and Race/Ethnicity,
Selected Areas in the United States
Sex/cancer site
Hispanicb Non-Hispanic White Black API
All race/
Ethnic groups
Rank Ratec APCd Rank Ratec APCd Rank Ratec APCd Rank Ratec APCd Rank Ratec APCd Rank Ratec APCd
Male
All Sitese 444.1 1.1f 571.8 0.3 555.0 0.4 639.8 1.3f 385.5 0.6 562.1 0.4
Prostate 1 141.1 0.7 1 167.0 0.2 1 156.0 0.0 1 243.0 0.9 1 104.2 0.6 1 165.0 0.1
Lung and Bronchus 2 52.7 2.9f 2 92.3 1.6f 2 88.8 1.6f 2 110.6 2.8f 2 56.6 1.5f 2 89.6 1.7f
Colon and Rectum 3 52.4 0.8 3 65.1 1.2f 3 63.7 1.4f 3 70.2 0.3 3 52.6 0.8 3 64.2 1.3f
Urinary Bladder 4 22.2 0.8 4 39.3 0.1 4 40.4 0.1 5 18.3 0.2 6 17.8 0.8 4 38.2 0.1
Non-Hodgkin Lymphoma 5 19.8 1.5f 5 22.9 0.2 5 23.1 0.3f 8 16.6 1.2f 7 17.2 0.1 5 22.6 0.3f
Kidney and Renal Pelvis 6 16.9 2.2f 7 18.0 2.5f 7 18.0 2.5f 4 18.5 2.7f 11 9.8 2.2 7 17.9 2.5f
Stomach 7 16.1 2.0f 11 10.3 2.4f 11 9.7 2.3f 7 17.4 2.8f 5 20.0 3.1f 11 10.7 2.3f
Liver and Intrahepatic Bile Duct 8 14.8 2.9f 15 7.7 3.1f 15 7.2 3.4f 14 11.1 3.2f 4 22.1 0.1 13 8.2 3.3f
Leukemia 9 12.2 0.9 9 16.1 0.5 8 16.3 0.7 12 11.9 1.2f 9 10.1 1.2 9 15.9 0.6
Oral Cavity and Pharynx 10 11.4 3.0f 8 16.5 0.9f 9 15.9 0.7f 6 18.0 3.4f 8 11.6 2.7f 8 16.1 1.1f
Pancreas 11 11.1 0.9 10 12.9 0.4f 10 12.6 0.5f 9 15.8 0.8f 10 10.0 1.2 10 12.8 0.3
Larynx 12 6.8 3.5f 14 7.7 3.3f 14 7.3 3.4f 13 11.9 3.2f 16 3.4 3.3f 15 7.6 3.4f
Myeloma 13 6.5 1.0 16 6.8 0.5 16 6.3 0.6 10 12.6 0.1 15 4.1 3.7f 16 6.8 0.5
Brain and Other Nervous System 14 6.2 0.2 13 8.1 0.3 13 8.4 0.5 15 4.7 0.6 12 5.0 1.4 14 7.9 0.4
Esophagus 15 5.7 2.5f 12 8.8 0.7f 12 8.4 1.3f 11 12.1 4.7f 13 4.4 4.9f 12 8.6 0.4
Melanoma of the Skin 16 4.6 0.3 6 22.0 3.4f 6 22.5 3.2f 24 1.1 4.6f 19 2.4 2.5 6 20.5 3.1f
Thyroid 18 3.3 4.6f 18 4.2 5.5f 18 4.3 5.5f 19 2.3 4.9f 14 4.2 2.9f 18 4.1 5.4f
Female
All Sitese 327.2 0.6 422.9 0.0 421.1 0.1 383.8 0.3 303.3 0.1 415.3 0.1
Breast 1 92.6 0.9 1 131.2 0.4 1 130.8 0.5 1 111.5 0.3 1 91.2 0.7 1 128.2 0.5
Colon and Rectum 2 37.3 0.6 3 47.3 0.8 3 45.9 1.0f 2 53.5 0.1 2 38.0 0.6 3 46.7 0.9
Lung and Bronchus 3 26.7 0.2 2 56.9 0.6f 2 56.2 0.6f 3 50.3 0.1 3 28.7 0.2 2 54.7 0.5f
Corpus and Uterus, NOS 4 18.7 0.2 4 24.2 0.3 4 24.5 0.4 4 19.7 1.0f 4 16.3 0.7f 4 23.8 0.3
Non-Hodgkin Lymphoma 5 14.7 0.2 5 16.2 0.5f 5 16.5 0.3 7 11.1 1.1f 6 11.9 1.2 5 16 0.4
Cervix Uteri 6 14.7 4.1f 13 8.6 3.9f 13 8.6 3.4f 6 13.0 4.9f 9 9.3 6.5f 13 9.1 3.7f
Ovarye 7 11.4 1.3f 7 14.0 1.7f 7 14.3 1.7f 8 10.0 1.2 8 10.6 0.9 6 13.8 1.7f
Thyroid 8 11.2 4.9f 8 11.7 7.5f 8 12.0 7.2f 13 7.2 7.1f 5 13.9 4.6f 8 11.6 7.1f
Kidney and Renal Pelvis 9 9.4 1.8f 12 9.1 2.8f 12 9.3 2.7f 9 9.5 2.8f 14 4.9 3.1f 12 9.2 2.7f
Pancreas 10 9.4 0.2 10 9.9 0.7f 11 9.6 0.7f 5 13.2 0.3 10 8.5 0.9 9 9.9 0.6f
Stomach 11 9.1 0.7 16 4.8 1.7f 16 4.4 1.3f 11 9.0 2.0f 7 11.4 3.1f 16 5.1 1.3f
Leukemia 12 8.4 0.3 11 9.6 0.4 10 9.8 0.5 12 7.7 0.1 12 6.5 1.5 11 9.5 0.4
Urinary Bladder 13 5.9 1.6 9 10.1 0.0 9 10.3 0.0 14 6.8 0.9 15 4.6 0.6 10 9.8 0.1
Liver and Intrahepatic Bile Duct 14 5.8 0.2 18 2.8 1.4f 18 2.7 1.3f 16 3.6 0.4 11 8.3 0.2 18 3 1.5f
Brain and Other Nervous System 15 5.0 0.2 15 5.8 0.3 15 6.1 0.2 18 3.5 0.9 16 3.5 0.6 15 5.7 0.4
Myeloma 16 4.9 0.3 17 4.5 0.6 17 4.0 0.7 10 9.3 0.8 17 3.3 0.1 17 4.5 0.5
Oral Cavity and Pharynx 17 4.2 2.2 14 6.4 1.0f 14 6.2 1.1f 15 5.7 2.2f 13 5.8 0.0 14 6.2 1.1f
Melanoma of the Skin 18 4.1 1.0 6 14.2 4.1f 6 14.8 3.9f 28 0.9 1.1 19 2.0 4.4f 7 13.1 3.7f
Source: SEER and NPCR areas reported by the North American Association of Central Cancer Registries (NAACCR) as meeting high quality standards for the time periods selected.
APC: annual percent change; API: Asian/Pacific Islander; NOS: not otherwise specified.
a Cancers are sorted in descending order according to sex-specific rates for Hispanics/Latinos. More than 15 cancers may appear under male and female to include the top 15 cancers in every racial and ethnic
group.
b NHIA derived Hispanic origin. White, black, and API categories include Hispanics and non-Hispanics; the race categories are not mutually exclusive of ethnicity.
c Rates are average annual per 100,000 age-adjusted to the 2000 US Std Population (19 age groups - Census p25-1130). The data from 38 cancer registries [Alabama, Alaska, California, Colorado, Connecticut, Dela-
ware, District Of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hamp-
shire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Washington, West Virginia, Wisconsin] were included covering 82% of U.S. population, and 82% of the
white, 80% of the black, and 92% of the API race groups, and 90% of the Hispanics (regardless of race).
d Annual percent change (APC) based on rates that were age-adjusted to the 2000 US Std Population (19 age groups - Census p25-1130). The data from 30 cancer registries with data from 1995–2003 [California,
Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Montana, Nebraska, Nevada, New Hampshire, New Jer-
sey, New York, Pennsylvania, Rhode Island, Texas, Utah, Washington, West Virginia, Wisconsin] were included covering 73% of the total U.S. population, and 73% of the white, 65% of the black, and 88% of the API
race groups, and 88% of the Latinos (regardless of race).
e All sites excludes myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.
f APC is statistically significantly different from zero (two-sided P < .05).
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TABLE 5
US Death Rates (1999–2003) and Fixed Interval Trends (1995–2003) for the Top 15 Cancersa by Sex and Race/Ethnicityb
Sex/cancer site
Hispanicb Non-Hispanic White Black API AI/AN
All race/
Ethnic groups
Rank Ratec APCd Rank Ratec APCd Rank Ratec APCd Rank Ratec APCd Rank Ratec APCd Rank Ratec APCd Rank Ratec APCd
Male
All Sites 166.4 1.6e 248.1 1.5e 239.2 1.4e 331.0 2.4e 144.9 2.1e 153.4 2.9e 243.7 1.6e
Lung and Bronchus 1 37.2 2.3e 1 77.2 1.9e 1 73.8 1.8e 1 98.4 2.7e 1 38.8 1.3e 1 42.9 5.1e 1 74.8 2.0e
Prostate 2 22.1 3.3e 2 29.4 4.0e 2 26.7 4.1e 2 65.1 3.5e 4 11.8 5.9e 2 18.0 4.8e 2 29.1 4.1e
Colon and Rectum 3 17.5 1.0e 3 24.7 2.1e 3 23.7 2.2e 3 33.6 1.1e 3 15.3 1.4 3 15.9 2.5 3 24.3 2.1e
Liver and Intrahepatic
Bile Duct 4 10.7 1.1e 9 6.8 1.7e 9 6.3 1.9e 7 9.6 1.2 2 15.5 1.0 4 7.8 0.8 9 7.0 1.8e
Stomach 5 9.2 2.6e 11 6.0 3.9e 12 5.4 3.9e 5 12.4 3.6e 5 11.0 4.2e 5 7.1 1.3 10 6.1 3.7e
Pancreas 6 9.0 0.7 4 12.3 0.0 4 12.0 0.1 4 15.7 0.8 6 7.8 1.9e 7 6.2 2.3 4 12.2 0.1
Non-Hodgkin
Lymphoma 7 7.1 4.1e 6 10.0 2.0e 6 10.3 2.0e 11 6.8 3.3e 7 6.1 2.3 9 4.8 5.4 6 9.9 2.1e
Leukemia 8 6.5 1.3 5 10.2 0.7e 5 10.4 0.7e 8 8.8 1.9e 8 5.1 1.7 10 4.7 3.2 5 10.1 0.8e
Kidney and Renal
Pelvis 9 5.3 0.5 10 6.1 0.2 10 6.2 0.1 12 6.1 0.3 12 2.6 2.9 6 6.8 0.9 11 6.1 0.2
Esophagus 10 4.3 2.6e 7 8.0 0.7e 8 7.6 1.4e 6 10.7 4.6e 10 3.2 3.4 8 5.0 0.3 7 7.8 0.5e
Urinary Bladder 11 4.1 0.2 8 7.7 0.5e 7 7.9 0.5e 13 5.5 1.1e 11 2.9 1.6 13 2.6  8 7.5 0.6e
Myeloma 12 3.7 0.0 13 4.7 0.9e 13 4.4 0.6e 9 8.6 1.9e 14 1.9 5.3e 11 3.3 1.9 13 4.7 0.9e
Brain and Other
Nervous System 13 3.4 0.2 12 5.7 0.7e 11 5.9 0.7e 15 3.3 0.3 13 2.5 3.1 14 2.4 1.5 12 5.5 0.8e
Oral Cavity and Pharynx 14 2.9 4.1e 14 4.2 2.2e 15 3.8 1.9e 10 6.9 4.2e 9 3.6 1.7 12 3.1 2.9 14 4.1 2.3e
Larynx 15 2.0 5.9e 16 2.5 2.1e 16 2.2 2.1e 14 5.1 3.0e 15 0.9 2.9 15 1.8  16 2.4 2.3e
Melanoma of the Skin 17 1.0 3.7e 15 4.0 0.4 14 4.3 0.4 24 0.5 1.7 19 0.5 2.4 16 0.9  15 3.8 0.5
Female
All Sites 108.8 0.6e 167.7 0.8e 163.4 0.8e 192.4 1.0e 98.8 1.1e 111.6 1.2e 164.3 0.9e
Breast 1 16.3 2.6e 2 26.6 2.2e 2 25.4 2.4e 2 34.4 1.5e 2 12.6 0.3 2 13.8 2.2 2 26.0 2.3e
Lung and Bronchus 2 14.7 0.1 1 42.7 0.5e 1 42.0 0.4e 1 39.8 0.2 1 18.8 1.2 1 27.0 0.7 1 41.0 0.3e
Colon and Rectum 3 11.4 0.1 3 17.3 1.9e 3 16.4 2.0e 3 23.7 1.3e 3 10.5 1.6 3 11.1 3.4e 3 17.0 2.0e
Pancreas 4 7.5 0.8 4 9.4 0.2 5 9.0 0.2 4 12.5 0.5 4 6.9 0.5 4 5.9 0.7 4 9.2 0.1
Ovary 5 6.0 0.6 5 9.1 0.0 4 9.2 0.0 5 7.4 0.1 7 4.9 1.4 5 5.2 3.1 5 8.9 0.1
Stomach 6 5.2 2.1e 11 3.0 3.0e 13 2.7 2.8e 8 6.0 2.9e 6 6.7 4.1e 8 3.7 2.4 11 3.1 2.7e
Non-Hodgkin
Lymphoma 7 5.1 1.6 6 6.4 2.5e 6 6.7 2.6e 11 4.3 1.2 8 4.0 1.0 7 3.9 0.6 6 6.4 2.5e
Liver and Intrahepatic
Bile Duct 8 5.0 1.6e 12 2.9 0.4 12 2.8 0.5e 12 3.8 0.1 5 6.7 1.0 6 4.0 3.1e 12 3.0 0.7e
Leukemia 9 4.2 0.5 7 5.9 0.7e 7 5.9 0.6e 9 5.3 0.8 9 3.2 2.3e 10 3.3 1.6 7 5.8 0.7e
Cervix Uteri 10 3.4 3.6e 14 2.6 3.5e 14 2.4 3.2e 10 5.1 4.8e 10 2.5 4.2e 12 2.6 4.2 14 2.7 3.5e
Corpus and Uterus,
NOS 11 3.2 0.2 8 4.2 0.2 9 3.9 0.0 6 7.1 0.8 11 2.3 1.3 13 2.2 0.4 8 4.1 0.1
Myeloma 12 2.7 0.2 10 3.2 0.7e 10 2.9 0.7e 7 6.4 1.1e 12 1.6 0.0 11 3.0 2.1 10 3.2 0.8e
Brain and Other
Nervous System 13 2.5 0.9 9 3.7 1.2e 8 3.9 1.0e 16 2.2 1.2 13 1.5 3.3 15 1.6  9 3.7 1.2e
Kidney and Renal
Pelvis 14 2.4 0.0 13 2.8 0.8e 11 2.8 0.8e 15 2.8 0.9 15 1.2 0.6 9 3.3 2.4 13 2.8 0.8e
Gallbladder 15 1.5 4.5e 20 0.8 2.8e 20 0.8 3.0e 19 1.0 1.5 17 0.8 7.0e 14 1.6  20 0.8 2.9e
Urinary Bladder 16 1.3 2.5 15 2.3 0.5 15 2.3 0.3 14 2.9 1.3 16 1.0 1.0 18 1.2  15 2.3 0.5
Esophagus 17 1.0 1.6 17 1.8 0.2 17 1.7 0.4 13 3.0 3.0e 18 0.8 4.1 17 1.2  16 1.8 0.4
Oral Cavity
and Pharynx 19 0.9 0.5 18 1.6 2.7e 18 1.5 2.4e 17 1.8 4.7e 14 1.4 0.9 16 1.4  18 1.5 2.6e
Source: National Center for Health Statistics public-use data file for the total U.S.
APC: annual percent change; API: Asian/Pacific Islander; AI/AN: American Indian/Alaska Native; NOS: not otherwise specified.
a Cancers are sorted in descending order according to sex-specific rates for all races. More than 15 cancers may appear under male and female to include the top 15 cancers in every racial and ethnic group.
b Data for Hispanics excludes Maine, Minnesota, New Hampshire, North Dakota, and Oklahoma. NHIA derived Hispanic origin. White, black, and API categories include Hispanics and non-Hispanics; the race
categories are not mutually exclusive of ethnicity.
c Rates are per 100,000 age-adjusted to the 2000 US Std Population (19 age groups - Census p25-1130) for the time period 1999–2003.
d Annual percent change (APC) based on rates that were age-adjusted to the 2000 US Std Population (19 age groups - Census p25-1130).
e APC is statistically significantly different from zero (two-sided P < .05).
 Statistic could not be calculated. The annual percent change is based on fewer than 10 cases for at least 1 year within the time interval.
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women experienced less of a decline in death rates for
all cancers combined from 1995 through 2003, and
Latina, white, black, and API women had fewer sites
with declining death rate trends. For breast cancer,
death rates declined from 1995 through 2003 in Latinas,
non-Latinas, white, and black, but were stable in API
and AI/AN, women. Lung cancer death rates continued
to increase from 1995 through 2003 in white and non-
Hispanic women, but were stable in other race/ethnic
populations, although among white women it deceler-
ated. Death rates for cancer of the colon and rectum
declined in women of most races and ethnicities, ex-
cept Latina and API. Death rates declined in 11 of 18
cancers in non-Latinas and 4 of 18 cancers in Latinas;
the differences were seen for cancers of the colon and
rectum, brain, kidney, and oral cavity, leukemia, NHL,
and myeloma, where rates were stable in Latinas; liver
cancer, where rates were increasing for Latinas; and
lung cancer, where rates were increasing in white, but
stable in Latina, women.
Cancer Among U.S. Latinos, 1999–2003
General characteristics
In the 2000 U.S. Census, 13% of the population stated
they were of Hispanic/Latino origin, second in size
only to the NHW population. From 1990 to 2000, the
U.S. Hispanic population grew by 58%,43 while the
total U.S. population grew by 13%. The U.S. Latino
population is younger (median age, 25.9 years) than
the general U.S. population (median age, 35.3 years).
Most U.S. Latinos live in California (28%), followed by
Texas (17%).43 The U.S. Hispanic population in 2000
was composed of Mexican (59%), Puerto Rican (10%),
Central American (5%), South American (4%), Cuban
(4%), and Dominican (2%) descent, with the remain-
ing 16% all other Latinos combined.
The specific Hispanic populations are not ran-
domly located across the U.S. For example, 31% of the
Latino population in Florida is Cuban, compared with
0.7% of the Latino population in California. Nearly
one-quarter of the Hispanics in Maryland are Central
American, while in neighboring Pennsylvania only
2.5% are Central American, with most Latinos in this
state being Puerto Rican. More state characteristics of
the Latino ethnic groups are available elsewhere.10,44
U.S. Latinos differ not only by geography but also
by socioeconomic characteristics (Table 6). (A data
table of statistical test results and 95% CI is available
at: www.seer.gov/report_to_nation/1975_2003/). Puerto
Ricans are the most likely of any Latino or race group
to live below the poverty level. Mexicans are the least
likely of all race/ethnic populations to have graduated
high school, and Cubans are the most linguistically
isolated (i.e., no person aged 14 years or older at
home speaks English very well) and most likely to be
foreign-born.
Compared with non-Latinos, Latinos are more
likely to speak a language other than English at home
and to reside in a metropolitan area. Latinos are less
likely than non-Latinos to have health care coverage,
especially when they are younger than 65 years. His-
panic persons are much less likely to have a regular
source of medical care than are non-Hispanic popula-
tions, with Latino men being the least likely.
Risk/Prevention/Early Detection
Cuban men and women had similar smoking rates
and were more likely than any of the other Latino
groups to smoke (Table 6); Puerto Rican and Mexican
women were the least likely. Cuban men were the
least likely to be obese and Puerto Rican women were
more likely, based on self-report, to be obese than all
other gender-race/ethnic groups, except NHB women.
Cuban women were less likely to have leisure time
physical activity while this characteristic for Puerto
Rican and Mexican women was similar to NHB women.
Reporting at least 1 day in the last year when 5 or more
alcoholic drinks were consumed was more common
among men than women, and among males, it was
less common among Cubans.
The 3 major Latino population groups were less
likely to have either a fecal occult blood test or an endos-
copy than were NHW or NHB groups. Pap testing and
mammography screening were comparable among all
Latinas, but only Pap tests occurred less in Latinas than
in NHW and NHB women. Latino men were less likely
than NHWmen to have had a PSA test in the last year.
Cancer Incidence
Latinos had lower incidence rates than NHW or NHB
populations for the majority of specific cancer sites,
including lung, colon and rectum, breast, and prostate
cancers (Table 7). Incidence rates that were higher in
Latinos than in NHW populations included cancers of
the stomach and liver in both males and females and
myeloma and cervical cancer in Latinas. Cancer of the
liver had more than a 2-fold incidence in Latinos than
in NHW persons. Incidence rates that were higher in
Latinos than in NHB populations were cancers of the
liver and brain, NHL, and melanoma regardless of gen-
der; cancers of the bladder and testis in Latino men;
and leukemias and cancers of the cervix, ovary, and
thyroid in Latinas.
In addition to the cancer sites in Table 7, Latino
men and women had lower rates than NHW men and
women for cancers of the small intestine, soft tissue
and heart, anus, and eye and orbit. (A data table of sta-
tistical test results and 95% CI is available at: www.
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TABLE 6
Socioeconomic Characteristics, Cancer Risk Factors, and Use of Cancer Screening by Race and Ethnicity, United Statesa
Characteristics
Hispanic Non-Hispanic
All Mexican Puerto Rican Cuban Whiteb Blackc
Socioeconomic Characteristics
% of persons with income below poverty leveld 22.6 23.5 25.8 14.6 8.1 24.8
% of persons (age  25 yrs) graduated high schoold 52.4 45.8 63.3 62.9 85.5 72.4
% of persons (age  25 yrs) with less than 9th graded 27.8 33.8 15.7 18.5 4.6 7.8
% of household linguistic isolationd 26.4 27.5 18.5 34.8 1.0 1.0
% of persons foreign bornd 40.2 41.5 1.4 68.5 3.5 5.7
% of persons with a language other than
English in the homed 78.6 78.8 75.4 86.3 6.0 6.0
% of persons inside metropolitan aread 93.4 92.3 96.3 97.2 73.6 89.6
Access to Health Care Characteristics
% of persons with no health care coveragee
Age < 65 years old 35.1 38.3 — — 12.0 18.6
Age  65 years old 5.3 6.7 — — 0.6 2.0
% of persons (Ages 18—64) with no regular
source of medical caref
Male 30.0 32.7 — — 14.9 17.5
Female 17.3 18.8 — — 7.9 9.1
Cancer Risk Factors
% of persons (age  18 yrs) who are current smokersf
Male 21.2 22.0 26.1 29.8 24.6 25.4
Female 10.3 8.9 14.5 30.0 22.1 18.3
% of persons (age  20 yrs) who are obese, (self-report)f#
Male 23.2 25.2 27.7 17.3 23.1 28.5
Female 28.0 30.7 32.0 19.0 21.3 38.5
% of persons (age  20 yrs) who are obese, (measured)g#
Male — 27.8 — — 28.0 27.8
Female — 38.0 — — 30.7 48.8
% of persons (age > 18 yrs) with no leisure time
physical activityf
Male 50.6 51.7 49.5 57.8 31.5 45.1
Female 52.7 52.3 51.4 70.0 35.1 50.5
% of persons (age > 18 yrs) with 5 or more drinks in
one day at least once in the past yearf
Male 24.4 26.4 22.0 12.3 29.8 17.6
Female 6.2 6.6 5.8 4.9 14.4 5.5
Use of Cancer Screening
Use of mammography in women (age  40 yrs)f
within the past 2 years 66.1 63.4 65.3 73.7 70.4 70.4
Use of colorectal cancer screening in adult
(age  50 yrs)f 29.9 26.2 35.9 31.4 44.2 38.9
Fecal occult blood test within last year 11.9 11.8 12.8 10.7 16.3 16.4
Endoscopy within past five years 25.1 20.4 32.8 24.8 37.4 32.6
Use of Pap smear in women (age  18 yrs)e
within the past 3 years 74.7 73.0 76.2 77.5 80.2 82.5
Use of PSA test in men (age  50 yrs)
within one yearf 52.7 46.3   58.0 55.6
a Data to assess precision of estimates are available as supplemental information at NCI website.
b Single race reported as white only.
c Single race reported as black only.
d Source: Tables PCT142, QTP20, PCT42, PCT1, PCT45, PCT178, and PCT2. U.S. Census Bureau, 2000 Census of Population and Housing Summary File 4.
e Schiller JS, Adams PF, Nelson ZC. Summary health statistics for the U.S. population: National Health Interview Survey, 2003. Vital Health Stat 10. 2005 Apr;(224):1—104.
f Source: National Health Interview Survey (NHIS), 2003, Sample adult file (Samadult Data), National Center for Health Statistics, Centers for Disease Control and Prevention. Available at http://www.cdc.gov/
nchs/nhis.htm.
g National Center for Health Statistics, Health, United States 2005, with Chartbook on Trends in the Health of Americans, Hyattsville, Maryland, Table 73. NHANES: National Health and Nutrition Examination Sur-
vey, 19992002.
# Body mass index (BMI) > 30.
— No data available.
 Data suppressed due to small numbers of less than 50 persons.
1722 CANCER October 15, 2006 / Volume 107 / Number 8
seer.gov/report_to_nation/1975_2003/). Latino men
and women had higher rates than NHW men and
women for gallbladder cancer, hepatocellular carci-
noma, and acute lymphocytic leukemia (ALL). Cancer
of the vagina was higher in Latinas than in NHW
women and cancer of the penis and Kaposi Sarcoma
(KS) were higher among Latinos than NHWmen.
Compared with NHB populations, Latinas had
lower rates of cancer of the vagina and Latino males
had lower rates of KS. However, Latinos had higher
TABLE 7
Age-adjusted Incidence Ratesa for the Top 15 Cancer Sitesb for each Sex by Race/Ethnicity in the Selected Areasc in the United States, 1999–2003
Sex/cancer site
Hispanicd
Non-Hispanic Hispanic c.f. Hispanic c.f.
White Black Non-Hispanic White Non-Hispanic Black
Rank Rate Rank Rate Rank Rate RR 95% CI RR 95% CI
Male
All Sites 444.1 565.6 650.2 0.79 (0.78–0.79)e 0.68 (0.68–0.69)e
Prostate 1 141.1 1 157.9 1 246.7 0.89 (0.88–0.90)e 0.57 (0.57–0.58)e
Lung and Bronchus 2 52.7 2 91.7 2 112.8 0.57 (0.57–0.58)e 0.47 (0.46–0.48)e
Colon and Rectum 3 52.4 3 64.6 3 71.3 0.81 (0.80–0.82)e 0.73 (0.72–0.75)e
Urinary Bladder 4 22.2 4 41.8 5 18.5 0.53 (0.52–0.55)e 1.20 (1.16–1.24)e
Non-Hodgkin Lymphoma 5 19.8 6 23.4 8 16.9 0.85 (0.83–0.87)e 1.17 (1.13–1.21)e
Kidney and Renal Pelvis 6 16.9 7 18.1 4 18.9 0.93 (0.91–0.96)e 0.89 (0.86–0.93)e
Stomach 7 16.1 11 9.2 7 17.6 1.75 (1.70–1.81)e 0.91 (0.88–0.95)e
Liver and Intrahepatic Bile Duct 8 14.8 16 6.5 14 11.2 2.28 (2.21–2.35)e 1.32 (1.27–1.38)e
Leukemia 9 12.2 8 16.6 13 12.1 0.74 (0.71–0.76)e 1.01 (0.97–1.05)
Oral Cavity and Pharynx 10 11.4 9 16.4 6 18.3 0.70 (0.68–0.72)e 0.62 (0.60–0.65)e
Pancreas 11 11.1 10 12.7 9 16.1 0.87 (0.84–0.91)e 0.69 (0.66–0.72)e
Larynx 12 6.8 14 7.4 12 12.1 0.91 (0.87–0.95)e 0.56 (0.53–0.59)e
Myeloma 13 6.5 17 6.3 10 12.8 1.04 (0.99–1.09) 0.51 (0.48–0.54)e
Brain and Other Nervous System 14 6.2 12 8.7 15 4.8 0.71 (0.69–0.74)e 1.29 (1.22–1.37)e
Esophagus 15 5.7 13 8.7 11 12.3 0.66 (0.63–0.70)e 0.47 (0.44–0.49)e
Melanoma of the Skin 16 4.6 5 24.4 24 1.1 0.19 (0.18–0.20)e 4.19 (3.75–4.69)e
Testis 17 3.6 15 6.5 23 1.3 0.55 (0.53–0.57)e 2.68 (2.48–2.90)e
Female
All Sites 327.2 430.2 389.9 0.76 (0.76–0.76)e 0.84 (0.83–0.84)e
Breast 1 92.6 1 134.4 1 113.4 0.69 (0.68–0.70)e 0.82 (0.81–0.83)e
Colon and Rectum 2 37.3 3 46.5 2 54.3 0.80 (0.79–0.81)e 0.69 (0.67–0.70)e
Lung and Bronchus 3 26.7 2 58.7 3 51.3 0.46 (0.45–0.46)e 0.52 (0.51–0.53)e
Corpus and Uterus, NOS 4 18.7 4 25.0 4 19.9 0.75 (0.73–0.77)e 0.94 (0.91–0.97)e
Non-Hodgkin Lymphoma 5 14.7 5 16.7 7 11.2 0.88 (0.86–0.90)e 1.31 (1.26–1.35)e
Cervix Uteri 6 14.7 13 7.9 6 13.2 1.85 (1.80–1.89)e 1.11 (1.08–1.15)e
Ovary 7 11.4 7 14.6 8 10.2 0.78 (0.76–0.80)e 1.12 (1.08–1.16)e
Thyroid 8 11.2 8 12.3 13 7.3 0.92 (0.89–0.94)e 1.53 (1.48–1.59)e
Kidney and Renal Pelvis 9 9.4 12 9.2 9 9.6 1.02 (0.99–1.05) 0.98 (0.94–1.02)
Pancreas 10 9.4 11 9.6 5 13.4 0.98 (0.95–1.01) 0.70 (0.68–0.73)e
Stomach 11 9.1 16 4.0 11 9.1 2.28 (2.20–2.36)e 1.01 (0.96–1.05)
Leukemia 12 8.4 10 9.8 12 7.8 0.86 (0.83–0.88)e 1.07 (1.03–1.12)e
Urinary Bladder 13 5.9 9 10.6 14 6.9 0.55 (0.53–0.58)e 0.85 (0.81–0.90)e
Liver and Intrahepatic Bile Duct 14 5.8 21 2.5 16 3.7 2.37 (2.27–2.48)e 1.59 (1.50–1.69)e
Brain and Other Nervous System 15 5.0 15 6.2 18 3.6 0.81 (0.78–0.84)e 1.41 (1.33–1.49)e
Myeloma 16 4.9 17 4.0 10 9.4 1.23 (1.17–1.29)e 0.52 (0.49–0.54)e
Oral Cavity and Pharynx 17 4.2 14 6.4 15 5.8 0.66 (0.63–0.69)e 0.72 (0.68–0.77)e
Melanoma of the Skin 18 4.1 6 16.2 28 0.9 0.26 (0.24–0.27)e 4.36 (3.97–4.80)e
Source: SEER and NPCR areas reported by the North American Association of Central Cancer Registries as meeting high quality standards for 1999–2003.
a Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) and confidence intervals (CI) are 95% for rate ratios (RR); c.f. ¼ compared with.
b 15 most common cancer in Hispanic males and females.
c The data from 38 cancer registries [Alabama, Alaska, California, Colorado, Connecticut, Delaware, District Of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Mary-
land, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Washington,
West Virginia, Wisconsin] were included covering 82% of U.S., 90% of the Hispanic, 81% of NHW and 79% of NHB populations.
d NHIA derived Hispanic origin.
e Rate ratio (RR) is statistically significant (P < 0.05).
2006 Annual Report on the Status of Cancer/Howe et al. 1723
rates than did NHB populations for mesothelioma;
ALL; and cancers of the gallbladder, bones and joint,
ureter, and eye and orbit. Latino men also had higher
rates of cancer of the penis than did NHB men and
Latinas had higher rates of ALL than did NHB women.
Dissimilar to all other smoking-related sites, Latino
men and women had higher rates of lip cancer than
did NHB men and women.
Site-Specific Rates by Age
The median age at any cancer diagnosis was the
youngest among Latinos at 62 years; while the median
age of NHB patients was 64 years and NHW cases, 68
years, reflecting differences in the age structures of
the 3 populations and the specific cancer mix. For
female breast, prostate, colon and rectum, lung, and
cervical cancer, the Latino cancer incidence rates
were the lowest, even within age categories (i.e., 20–
39, 40–49, 50–64, 65–74, 75þ years), among the 3
race/ethnic groups, with the exception of cervical
cancer in Latinas younger than 65 years (highest rates
among all 3 groups) and prostate cancer in Latino
men, aged 75 years and older (higher than NHW, but
not NHB, men). (A data table is available at: www.
seer.gov/report_to_nation/1975_2003/).
Cancer in Latino Children and Adolescents
Incidence rates for all cancers combined were lower
among Latino than NHW boys (aged 0–14) and Latino
adolescents of each sex (aged 15–19), but rates were
higher among Latinos than all NHB children and ado-
lescents (Table 8). Cancer-specific rates among Latino
children and adolescents were generally similar or
higher than those of NHB groups (with the exception
of renal tumors in all Latino children and soft tissue
sarcomas in male adolescents), and thus comparisons
that follow are limited to Latino and NHW children
and adolescents.
Of the 12 major cancer groups, Latino boys had
lower incidence rates for CNS tumors, neuroblastoma
and other peripheral nervous cell tumors (neuroblas-
tomas), renal tumors, and other malignant epithelial
neoplasms and melanomas (epithelial neoplasms) and
higher incidence rates, than did NHW boys, for leuke-
mias, retinoblastoma, and germ-cell tumors. Incidence
rates for Hodgkin lymphomas and osteosarcomas were
also higher among Latino than NHW boys, although
the combined rates for all lymphomas and reticuloen-
dothelial neoplasms (lymphomas) and for all malig-
nant bone tumors (bone tumors) were not different.
The difference in leukemias incidence rates between
Latino and NHW adolescents was greater than it was
between children of the 2 groups. For osteosarcomas
and germ-cell tumors, the differences observed in
Latino, compared with NHW children, disappeared in
adolescents. In contrast to these patterns, incidence
rates for Hodgkin lymphomas were similar among
Latino and NHW boys, but lower among Latino, than
NHWmale, adolescents.
Latina girls, aged 0–14 years, had lower incidence
rates of CNS tumors, neuroblastomas, renal tumors,
and epithelial neoplasms and higher incidence rates
than did NHW girls for leukemias, retinoblastoma, and
germ-cell tumors. Incidence rates of osteosarcomas
were higher among Latina than NHW girls, although
the rate of all bone tumors was similar. The difference
in incidence rates between Latinas and NHW female
adolescents disappeared for osteosarcomas, but re-
mained for leukemias and germ-cell tumors.
County Poverty and Cancer Incidence
As county poverty increased, the cancer incidence rates
of liver (including hepatocellular carcinoma in both
men and women) and cervix (women) increased in
Latinos, a pattern similar to other race/ethnic groups
(Table 9). Cancer incidence rates of the prostate, breast
(female), bladder (men and women), and uterine cor-
pus (excluding NHB women) in all race/ethnic groups
were highest in counties with less than 10% poverty.
The RRs of the higher poverty compared with <10%
poverty counties were lower for cancers of the colon and
rectum and bladder among Latinos and Latinas and
breast (Latina) than in the other 2 race/ethnic groups.
Cancer Among Latino Population Groups
After age-adjustment, the proportion of liver cancer
was higher among all Latino groups when each was
compared with NHW persons (Table 10); cancers of the
stomach and gallbladder were proportionally higher
among all groups when each was compared with the
NHW population (except stomach cancer in Cuban
males and gallbladder cancer in Cuban females). Pros-
tate cancer was proportionally higher in Cubans and
South/Central Americans than in NHWmen, and lower
in Mexicans than in NHW men. Kidney cancer was
higher in Mexicans of both sexes and lower in the other
specific Latino groups when compared with NHWmen
and women. Conversely, breast cancer in each Latina
group was proportionally lower than in NHW women,
as was lung cancer for both Latinomen and women.
Stage of Disease at Diagnosis
Latinos were less likely to be diagnosed with localized
disease (among selected cancers, i.e. breast, cervix,
prostate, lung, and colon and rectum) than were
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TABLE 8
Cancer Incidence Ratesa for Selected Pediatric and Adolescent Cancer Sites by Age, Race/Ethnicity and Sex in the Selected Areasb in the
United States, 1999–2003
Gender/cancer site
Hispanicc
Non-Hispanic Hispanic c.f. Hispanic c.f.
White Black Non-Hispanic White Non-Hispanic Black
Rate Rate Rate RR 95% CI RR 95% CI
Male
All Sites
0–14 159.0 165.3 110.2 0.96 (0.93–1.00)d 1.44 (1.37–1.52)d
15–19 209.5 234.1 147.8 0.90 (0.85–0.95)d 1.42 (1.30–1.54)d
I. Leukemias, myeloproliferative and
myelodysplastic diseases
0–14 58.6 50.9 25.9 1.15 (1.08–1.22)d 2.26 (2.04–2.51)d
15–19 45.9 32.5 24.5 1.41 (1.24–1.60)d 1.87 (1.54–2.28)d
Lymphoid leukemias (comprised mostly
of Acute Lymphocytic Leukemia)
0–14 47.4 40.8 17.4 1.16 (1.09–1.24)d 2.73 (2.41–3.09)d
15–19 29.3 19.8 11.8 1.48 (1.26–1.74)d 2.49 (1.90–3.30)d
Acute myeloid leukemias
0–14 07.9 07.6 06.7 1.04 (0.88–1.23) 1.18 (0.94–1.49)
15–19 11.1 09.3 09.1 1.20 (0.93–1.55) 1.22 (0.86–1.75)
II. Lymphomas and reticuloendothelial
neoplasms
0–14 20.7 20.1 15.4 1.03 (0.93–1.14) 1.35 (1.16–1.56)d
15–19 44.0 57.7 39.1 0.76 (0.68–0.86)d 1.13 (0.95–1.34)
Hodgkin lymphomas
0–14 08.3 06.4 06.0 1.29 (1.09–1.52)d 1.38 (1.09–1.76)d
15–19 24.5 34.9 20.2 0.70 (0.60–0.82)d 1.21 (0.96–1.54)
Non-Hodgkin lymphomas
(except Burkitt lymphoma)
0–14 07.5 07.8 06.7 0.96 (0.81–1.13) 1.12 (0.89–1.41)
15–19 15.7 17.9 15.9 0.87 (0.71–1.07) 0.98 (0.74–1.30)
III. CNS and misc intracranial and
intraspinal neoplasms
0–14 29.5 37.6 24.4 0.78 (0.72–0.85)d 1.21 (1.08–1.36)d
15–19 20.1 25.5 14.6 0.79 (0.66–0.94)d 1.38 (1.05–1.81)d
Astrocytomas
0–14 13.1 17.6 11.3 0.74 (0.66–0.84)d 1.16 (0.97–1.38)
15–19 09.1 14.0 09.1 0.65 (0.49–0.84)d 1.00 (0.69–1.45)
Intracranial and intraspinal embryonal
tumors
0–14 07.8 10.1 05.7 0.77 (0.65–0.90)d 1.38 (1.08–1.76)d
15–19 05.9 04.1  1.43 (0.99–2.05)  
IV. Neuroblastoma and other peripheral
nervous cell tumors
0–14 07.7 12.9 08.5 0.60 (0.51–0.70)d 0.91 (0.73–1.12)
15–19  00.6     
V. Retinoblastoma
0–14 05.2 03.8 05.1 1.36 (1.11–1.68)d 1.02 (0.78–1.34)
15–19 00.0 00.0     
VI. Renal tumors
0–14 06.4 08.1 09.0 0.79 (0.66–0.94)d 0.71 (0.57–0.89)d
15–19  01.1     
Nephroblastoma and other nonepithelial
renal tumors
0–14 06.1 07.7 08.3 0.79 (0.66–0.94)d 0.74 (0.59–0.93)d
15–19   00.0    
VII. Hepatic tumors
0–14 02.4 02.5 01.9 0.95 (0.71–1.27) 1.29 (0.85–2.02)
15–19  01.2     
(continued )
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TABLE 8
(continued )
Gender/cancer site
Hispanicc
Non-Hispanic Hispanic c.f. Hispanic c.f.
White Black Non-Hispanic White Non-Hispanic Black
Rate Rate Rate RR 95% CI RR 95% CI
VIII. Malignant bone tumors
0–14 06.9 07.2 04.8 0.96 (0.80–1.14) 1.44 (1.11–1.88)d
15–19 18.2 20.1 15.9 0.91 (0.75–1.10) 1.14 (0.87–1.50)
Osteosarcomas
0–14 04.5 03.4 03.8 1.33 (1.05–1.68)d 1.17 (0.86–1.60)
15–19 11.4 11.7 12.4 0.97 (0.76–1.24) 0.91 (0.66–1.26)
Ewing tumor and related sarcomas of bone
0–14 01.7 03.3  0.52 (0.36–0.72)d  
15–19 05.0 06.4  0.77 (0.52–1.10)  
IX. Soft tissue and other extraosseous
sarcomas
0–14 11.2 11.3 09.4 1.00 (0.87–1.14) 1.20 (0.99–1.45)
15–19 14.7 15.9 20.2 0.93 (0.74–1.14) 0.73 (0.56–0.95)d
Rhabdomyosarcomas
0–14 05.5 06.0 05.0 0.91 (0.75–1.10) 1.10 (0.84–1.44)
15–19 03.2 04.9 05.3 0.66 (0.41–1.02) 0.61 (0.34–1.06)
X. Germ cell and trophoblastic tumors
and neoplasms of gonads
0–14 06.7 04.2 01.8 1.59 (1.31–1.92)d 3.74 (2.58–5.59)d
15–19 46.0 42.0 09.5 1.10 (0.97–1.24) 4.87 (3.67–6.57)d
XI. Other malignant epithelial neoplasms
and melanomas
0–14 03.2 06.0 03.6 0.53 (0.41–0.68)d 0.89 (0.63–1.25)
15–19 16.7 36.5 16.8 0.46 (0.38–0.55)d 1.00 (0.76–1.31)
Thyroid carcinomas
0–14 00.9 01.3  0.73 (0.44–1.18)  
15–19 04.3 06.4  0.67 (0.44–0.97)d  
Other and unspecified carcinomas
0–14 01.0 01.6 01.3 0.60 (0.37–0.95)d 0.73 (0.40–1.33)
15–19 07.4 10.7 08.0 0.69 (0.51–0.92)d 0.92 (0.62–1.39)
XII. Other and unspecified malignant
neoplasms
0–14  00.7     
15–19  00.9     
Female
All Sites
0–14 142.0 146.3 107.2 0.97 (0.93–1.01) 1.32 (1.25–1.40)d
15–19 163.7 216.5 135.8 0.76 (0.71–0.81)d 1.21 (1.10–1.32)d
I. Leukemias, myeloproliferative and
myelodysplastic diseases
0–14 53.5 43.1 24.8 1.24 (1.16–1.32)d 2.16 (1.94–2.41)d
15–19 28.3 21.7 17.7 1.30 (1.10–1.54)d 1.59 (1.25–2.04)d
Lymphoid leukemias (comprised mostly
of Acute Lymphocytic Leukemia)
0–14 43.0 34.1 17.0 1.26 (1.17–1.36)d 2.53 (2.23–2.88)d
15–19 15.8 10.3 06.8 1.53 (1.21–1.92)d 2.32 (1.60–3.43)d
Acute myeloid leukemias
0–14 08.1 06.9 06.3 1.17 (0.99–1.38) 1.28 (1.01–1.63)d
15–19 08.4 08.7 08.7 0.97 (0.72–1.31) 0.97 (0.65–1.44)
II. Lymphomas and reticuloendothelial
neoplasms
0–14 11.1 12.1 09.3 0.92 (0.79–1.05) 1.20 (0.98–1.46)
15–19 32.6 52.5 33.6 0.62 (0.53–0.72)d 0.97 (0.80–1.18)
(continued )
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TABLE 8
(continued )
Gender/cancer site
Hispanicc
Non-Hispanic Hispanic c.f. Hispanic c.f.
White Black Non-Hispanic White Non-Hispanic Black
Rate Rate Rate RR 95% CI RR 95% CI
Hodgkin lymphomas
0–14 04.0 05.0 03.3 0.80 (0.63–1.02) 1.22 (0.87–1.72)
15–19 21.5 40.3 21.0 0.53 (0.44–0.63)d 1.02 (0.80–1.31)
Non-Hodgkin lymphomas (except
Burkitt lymphoma)
0–14 04.5 04.5 04.4 1.00 (0.80–1.25) 1.03 (0.76–1.39)
15–19 08.3 10.7 11.6 0.77 (0.57–1.03) 0.71 (0.49–1.03)
III. CNS and misc intracranial and
intraspinal neoplasms
0–14 25.7 32.9 22.6 0.78 (0.71–0.85)d 1.14 (1.00–1.29)
15–19 13.5 20.9 12.8 0.65 (0.51–0.81)d 1.05 (0.77–1.45)
Astrocytomas
0–14 10.9 17.1 10.5 0.64 (0.56–0.73)d 1.04 (0.86–1.26)
15–19 07.0 12.1 06.7 0.58 (0.42–0.79)d 1.05 (0.67–1.64)
Intracranial and intraspinal embryonal
tumors
0–14 06.5 06.3 04.5 1.03 (0.85–1.24) 1.45 (1.10–1.91)d
15–19  02.7     
IV. Neuroblastoma and other peripheral
nervous cell tumors
0–14 07.1 12.5 07.3 0.57 (0.48–0.67)d 0.98 (0.78–1.24)
15–19  00.7     
V. Retinoblastoma
0–14 04.8 03.6 03.6 1.34 (1.08–1.67)d 1.35 (0.99–1.85)
15–19 00.0  00.0    
VI. Renal tumors
0–14 07.3 09.5 11.6 0.77 (0.65–0.91)d 0.63 (0.52–0.77)d
15–19  01.1     
Nephroblastoma and other nonepithelial
renal tumors
0–14 07.1 09.2 11.0 0.77 (0.65–0.91)d 0.65 (0.53–0.79)d
15–19 00.0      
VII. Hepatic tumors
0–14 02.0 01.8 01.2 1.08 (0.77–1.51) 1.70 (1.01–2.99)
15–19  01.2     
VIII. Malignant bone tumors
0–14 07.5 06.7 05.9 1.12 (0.93–1.33) 1.27 (0.99–1.63)
15–19 10.5 11.8 07.7 0.89 (0.68–1.16) 1.37 (0.93–2.03)
Osteosarcomas
0–14 04.6 03.4 05.0 1.36 (1.07–1.72)d 0.92 (0.69–1.23)
15–19 06.5 05.9 05.5 1.11 (0.78–1.57) 1.19 (0.74–1.94)
Ewing tumor and related sarcomas of bone
0–14 02.2 03.0  0.73 (0.53–1.00)  
15–19  04.2     
IX. Soft tissue and other extraosseous
sarcomas
0–14 09.8 09.5 10.4 1.03 (0.89–1.20) 0.94 (0.77–1.15)
15–19 14.4 14.1 13.7 1.02 (0.80–1.28) 1.05 (0.77–1.43)
Rhabdomyosarcomas
0–14 04.7 04.6 04.8 1.02 (0.81–1.26) 0.97 (0.73–1.30)
15–19 03.1 02.5  1.23 (0.71–2.03)  
X. Germ cell and trophoblastic tumors
and neoplasms of gonads
0–14 06.6 05.3 05.0 1.25 (1.03–1.51)d 1.32 (1.01–1.73)d
15–19 19.7 13.6 16.6 1.45 (1.18–1.78)d 1.19 (0.91–1.56)
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NHW, and about the same as NHB men (Table 11).
Latinas, however, were the least likely to be diagnosed
with cervical cancer in a distant stage, while all Lati-
nos were the most likely to be diagnosed with lung
cancer in a distant stage. NHW persons had the high-
est proportion of cases diagnosed in a localized stage
for all 5 cancer sites. The proportion of the cancers of
regional and distant stage combined was similar
across county poverty levels, except breast and cervi-
cal cancer among Latinas, where the combined per-
cent of regional and distant stages increased with
increasing county poverty. Compared with NHW men
and women, Latinos were more likely to be diagnosed
in the combined group of regional and distant stages
within each of the county poverty levels, although
NHB women had the highest proportion of cases
diagnosed at a distant stage among the 3 racial and
ethnic groups.
Regardless of ethnicity or race, the proportion of
cases diagnosed with an unknown stage for the
selected common cancer sites increased as the county
poverty level increased. Latino cases residing in coun-
ties of <10% poverty had the lowest proportions of
unstaged cases among the 3 populations, but in
20%þ poverty counties, the proportion of unstaged
cases exceeded that of NHW and NHB persons (e.g.,
cancers of the colon and rectum, prostate, and
breast).
Metropolitan and Nonmetropolitan Areas
The RRs between age-adjusted incidence rates were
higher in metropolitan than in nonmetropolitan
counties among the Latino, NHW, and NHB race/eth-
nic groups for cancers of the bladder, colon and rec-
tum, liver, and stomach for both men and women,
and higher for prostate cancer. (A data table is avail-
able at: www.seer.gov/report_to_nation/1975_2003/).
Lung cancer rates were lower for metro NHW and
NHB males, but not in Latino males; while in females,
the nonmetro Latina lung cancer rates were higher
than those of metro Latinas, opposite of the pattern
observed for NHW and NHB women. For cancers of
the uterine corpus, cervix, and breast, the metro/non-
metro gradient was not observed for Latinas, while
the metro rates were higher than nonmetro rates for
the other 2 race/ethnic female populations. Rate
ratios for gallbladder cancer did not suggest a metro/
nonmetro gradient for any race/ethnic group.
DISCUSSION
The overall decline in cancer death rates, first noticed
in the early 1990s,1 has continued through 2003. In
TABLE 8
(continued )
Gender/cancer site
Hispanicc
Non-Hispanic Hispanic c.f. Hispanic c.f.
White Black Non-Hispanic White Non-Hispanic Black
Rate Rate Rate RR 95% CI RR 95% CI
XI. Other malignant epithelial neoplasms
and melanomas
0–14 06.0 08.6 05.1 0.70 (0.58–0.84)d 1.18 (0.90–1.55)
15–19 41.4 77.0 28.0 0.54 (0.47–0.61)d 1.48 (1.22–1.81)d
Thyroid carcinomas
0–14 03.0 03.4 01.7 0.88 (0.66–1.16) 1.80 (1.15–2.85)d
15–19 24.7 35.1 08.9 0.70 (0.59–0.83)d 2.79 (2.03–3.88)d
Other and unspecified carcinomas
0–14 01.7 02.0 02.2 0.85 (0.58–1.23) 0.74 (0.46–1.18)
15–19 12.0 13.3 15.0 0.90 (0.70–1.15) 0.80 (0.58–1.09)
XII. Other and unspecified malignant
neoplasms
0–14  00.7     
15–19  01.8     
Source: SEER and NPCR areas reported by the North American Association of Central Cancer Registries as meeting high quality standards for 1999–2003.
a Rates for all ages 0–14 or 15–19 are per 1,000,000 and age-adjusted to the 2000 US Std Population.
b The data from 38 cancer registries [Alabama, Alaska, California, Colorado, Connecticut, Delaware, District Of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Mary-
land, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Washington,
West Virginia, Wisconsin] were included covering 82% of U.S., 90% of the Hispanic, 81% of NHW and 79% of NHB populations.
c NHIA derived Hispanic origin.
d Rate ratio (RR) is statistically significant (P < 0.05).
 Count and rates suppressed when cell frequency was <16.
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TABLE 9
Age-adjusted Incidence Ratesa and Rate Ratios for Selected Cancer Sitesb by Race/Ethnicity, County Poverty, and Sex in Selected Areasc of
the United States, 1999–2003
Sex/cancer site
County povertyd Hispanice Non-Hispanic White Non-Hispanic Black
(%) Rate RR (95% CI) Rate RR (95% CI) Rate RR (95% CI)
Male
Colon and Rectum
<10 56.3 1.00 64.2 1.00 70.1 1.00
10–19 51.6 0.92 (0.88–0.96)f 64.7 1.01 (1.00–1.02) 72.1 1.03 (0.99–1.06)
20 52.0 0.92 (0.87–0.97)f 66.6 1.04 (1.02–1.05)f 70.3 1.00 (0.96–1.04)
Gallbladder
<10 1.2 1.00 0.8 1.00 0.9 1.00
10–19 1.4 1.16 (0.84–1.61) 0.7 0.94 (0.88–1.02) 0.9 0.96 (0.70–1.33)
20 1.5 1.29 (0.88–1.88) 0.8 1.00 (0.85–1.18) 1.0 1.13 (0.78–1.62)
Liver and Intrahepatic
Bile Duct <10 12.9 1.00 6.1 1.00 9.7 1.00
10–19 14.4 1.12 (1.02–1.22)f 6.8 1.12 (1.09–1.15)f 11.4 1.17 (1.07–1.27)f
20 18.0 1.39 (1.26–1.54)f 7.5 1.24 (1.18–1.30)f 12.5 1.28 (1.16–1.41)f
Hepatocellular
<10 10.2 1.00 4.1 1.00 7.4 1.00
10–19 11.1 1.10 (0.99–1.21) 4.6 1.12 (1.09–1.16)f 8.6 1.16 (1.06–1.27)f
20 14.6 1.44 (1.29–1.61)f 5.3 1.28 (1.20–1.36)f 9.5 1.28 (1.15–1.43)f
Lung and Bronchus
<10 55.2 1.00 84.4 1.00 99.5 1.00
10–19 51.6 0.93 (0.89–0.98)f 96.2 1.14 (1.13–1.15)f 117.3 1.18 (1.15–1.21)f
20 54.6 0.99 (0.94–1.04) 103.3 1.22 (1.21–1.24)f 112.8 1.13 (1.10–1.17)f
Non-Hodgkin Lymphoma
<10 21.5 1.00 23.7 1.00 17.2 1.00
10–19 19.6 0.91 (0.85–0.98)f 23.3 0.99 (0.97–1.00)f 16.5 0.96 (0.90–1.02)
20 19.6 0.91 (0.84–0.99)f 22.0 0.93 (0.90–0.96)f 17.8 1.03 (0.96–1.11)
Prostate
<10 155.4 1.00 164.3 1.00 256.3 1.00
10–19 137.5 0.89 (0.86–0.91)f 154.6 0.94 (0.94–0.95)f 243.0 0.95 (0.93–0.96)f
20 141.1 0.91 (0.88–0.94)f 140.8 0.86 (0.85–0.87)f 246.3 0.96 (0.94–0.98)f
Stomach
<10 16.3 1.00 9.1 1.00 16.4 1.00
10–19 15.6 0.96 (0.88–1.04) 9.1 1.00 (0.98–1.02) 17.9 1.09 (1.02–1.18)f
20 17.3 1.06 (0.96–1.17) 9.6 1.05 (1.00–1.10)f 18.2 1.11 (1.02–1.21)f
Urinary Bladder
<10 27.7 1.00 42.9 1.00 19.8 1.00
10–19 22.3 0.80 (0.75–0.86)f 41.4 0.97 (0.96–0.98)f 18.5 0.94 (0.87–1.00)
20 17.4 0.63 (0.57–0.69)f 37.7 0.88 (0.86–0.90)f 17.6 0.89 (0.82–0.96)f
Female
Cervix Uteri
<10 13.5 1.00 7.2 1.00 11.2 1.00
10–19 14.7 1.09 (1.03–1.16)f 8.5 1.18 (1.15–1.21)f 13.0 1.16 (1.09–1.24)f
20 15.9 1.18 (1.09–1.27)f 9.3 1.30 (1.24–1.36)f 15.5 1.39 (1.29–1.49)f
Colon and Rectum
<10 41.3 1.00 46.7 1.00 54.0 1.00
10–19 37.2 0.90 (0.86–0.94)f 46.3 0.99 (0.98–1.00) 54.9 1.02 (0.99–1.05)
20 34.5 0.83 (0.79–0.88)f 47.6 1.02 (1.00–1.04)f 53.2 0.99 (0.95–1.02)
Corpus and Uterus, NOS
<10 19.8 1.00 26.3 1.00 19.8 1.00
10–19 18.5 0.94 (0.88–0.99)f 24.1 0.92 (0.91–0.93)f 19.5 0.99 (0.94–1.04)
20 18.6 0.94 (0.87–1.01) 23.5 0.90 (0.87–0.92)f 21.0 1.06 (1.00–1.13)f
Female breast
<10 105.4 1.00 136.6 1.00 115.4 1.00
10–19 91.8 0.87 (0.85–0.89)f 133.4 0.98 (0.97–0.98)f 114.7 0.99 (0.97–1.01)
20 85.0 0.81 (0.78–0.83)f 126.5 0.93 (0.92–0.94)f 108.1 0.94 (0.91–0.96)f
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addition, many cancer sites have declining death and
incidence rates. These are attributable in part to suc-
cessful cancer prevention efforts to reduce exposure
to tobacco and other cancer risk factors, earlier detec-
tion of disease through screening, improved prognosis
through more effective treatment, and reduction in
inequalities in cancer care through more widespread
access to effective diagnostic and treatment regimens
by the general population. These all point to the suc-
cess of the nation’s dedication and focus on reducing
the burden of cancer in the U.S. Continued success will
depend on maintaining and enhancing these efforts.45
Overall Cancer Incidence and Mortality
Trends in the United States
Some site-specific trends are more variable, affecting
annual interpretation of incidence statistics. The join-
point regression model suggests a small increase in the
female lung cancer incidence rate from 1991 through
2003, a change from previous estimates,7,8 where rates
from 1998 through 2002 appeared stable.8 Using the
fixed-interval (1995–2003) lung cancer trend to com-
pare age-specific trends, rates were increasing in
women for all age groups 65 years and older, de-
creasing among women aged 45–64 years, and stable
in women younger than 45 years. In men, however,
lung cancer rates were decreasing in all age groups.
Women in the oldest cohort, with the highest propor-
tion of long-term smokers, will continue to have the
greatest impact on the trends, until the younger co-
horts move into the age groups of highest lung cancer
incidence.46,47
This year the previously reported increase8 in
breast cancer incidence rates stabilized. Most regis-
TABLE 9
(continued )
Sex/cancer site
County povertyd Hispanic
e Non-Hispanic White Non-Hispanic Black
(%) Rate RR (95% CI) Rate RR (95% CI) Rate RR (95% CI)
Gallbladder
<10 3.0 1.00 1.3 1.00 1.5 1.00
10–19 3.1 1.04 (0.88–1.22) 1.2 0.94 (0.90–0.99)f 1.6 1.05 (0.87–1.27)
20 2.9 0.98 (0.81–1.20) 1.3 1.00 (0.90–1.11) 2.1 1.35 (1.10–1.67)f
Liver and Intrahepatic
Bile Duct <10 4.7 1.00 2.3 1.00 3.4 1.00
10–19 5.8 1.25 (1.10–1.43)f 2.5 1.10 (1.06–1.14)f 3.6 1.07 (0.95–1.21)
20 6.8 1.45 (1.25–1.68)f 3.0 1.29 (1.20–1.39)f 4.0 1.17 (1.02–1.35)f
Hepatocellular
<10 2.8 1.00 1.1 1.00 1.9 1.00
10–19 3.7 1.31 (1.11–1.56)f 1.3 1.10 (1.05–1.16)f 2.1 1.11 (0.95–1.31)
20 4.7 1.67 (1.39–2.02)f 1.4 1.23 (1.10–1.37)f 2.7 1.41 (1.18–1.69)f
Lung and Bronchus
<10 32.7 1.00 56.5 1.00 51.1 1.00
10–19 26.2 0.80 (0.76–0.84)f 60.3 1.07 (1.06–1.08)f 52.1 1.02 (0.99–1.05)
20 23.6 0.72 (0.68–0.77)f 60.2 1.07 (1.05–1.08)f 49.7 0.97 (0.94–1.01)
Stomach
<10 9.8 1.00 3.9 1.00 8.2 1.00
10–19 8.9 0.90 (0.83–0.99)f 4.0 1.02 (0.99–1.05) 9.1 1.12 (1.03–1.21)f
20 9.5 0.97 (0.87–1.08) 4.7 1.20 (1.13–1.26)f 9.5 1.16 (1.06–1.27)f
Urinary Bladder
<10 8.0 1.00 11.1 1.00 7.3 1.00
10–19 5.7 0.72 (0.64–0.80)f 10.4 0.94 (0.92–0.95)f 6.9 0.94 (0.86–1.03)
20 4.8 0.60 (0.53–0.69)f 10.0 0.90 (0.87–0.93)f 6.7 0.91 (0.82–1.01)
Source: SEER and NPCR areas reported by the North American Association of Central Cancer Registries as meeting high quality standards for 1999–2003.
a Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census p25-1130) standard and confidence intervals (CI) are 95% for rate ratios (RR).
b Top 5 common cancers regardless of race/ethnicity and the selected cancer sites for which Hispanic persons have the higher incidence rates than non-Hispanic white persons.
c The data from 37 cancer registries [Alabama, Alaska, California, Colorado, Connecticut, Delaware, District Of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland,
Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Washington, West
Virginia, Wisconsin] were included covering 82% of U.S., 90% of the Hispanic, 81% of NHW and 79% of NHB populations. No county identifiers were available for Hawaii.
d Percent (%) of county population below poverty in 1999.
e NHIA derived Hispanic origin.
f Rate ratio is statistically significantly (P < 0.05).
NOS: Not otherwise specified.
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tries in the SEER regions, upon which the long-term
trends statistics are based, reported a steep decline in
the number of 2003 breast cancer cases; rates were
lower in all but 2 of the 30 states included in the
1995–2003 fixed-interval trend statistics (data not
shown). The factors that influence breast cancer inci-
dence are complex, including changes in reproductive
risks, obesity, age-cohort effects, and the prevalence
of mammography screening, among others. Recent
reports hypothesize about the impact of the rapid dis-
continuation of hormone replacement therapy (HRT)
on breast cancer incidence.48,49 HRT is a known risk
factor for breast cancer.48,49 Change, even stabilization,
in mammography screening prevalence also affects
incidence trends.48 Whether this first indication of a
changing trend is real or a random fluctuation cannot
be determined until data reporting in the next few
years is complete.
The fixed interval incidence trend of thyroid can-
cer has increased in both men and women, with long-
term increases in women doubling twice in the last
10 years. Increases are observed in all U.S. racial and
ethnic populations and all age groups, as well as glob-
ally.50–54 Although not in the top 15 causes of death,
long-term thyroid cancer death rate trends decreased
in men from 1975 to 1983 and in women from 1975 to
1988. They have increased in men from 1983 through
2003 and have been stable in women from 1988 to
2003.13 Changes in diagnostic procedures, including
the introduction and greater use of ultrasonography
and fine-needle aspiration biopsy, likely contribute to
the incidence increase.50,51,55,56 Radiation exposure in
childhood and adolescence is also a recognized risk
factor.57,58 More research on the relation among tem-
poral trends, diagnostic procedures, and exposure to
radiation and other potential risk factors is needed.
TABLE 10
The Proportional Incidence Ratio (PIR) for Selected Cancers among Hispanic Subgroups using the Age-specific Proportions among
the Non-Hispanic White Population as the Reference, Selected Areasa in the United States, 1999–2003
Non-Hispanic
White Mexican Puerto Rican Cuban
South or
Central American
Hispanic of other/
Unknown originb
PIR with 95% CI for Males
Hispanic subgroup distribution (%) 17.3 7.6 6.1 6.7 62.3
Stomach 1.00 3.03 (2.87–3.20) 2.22 (2.02–2.43) 1.11 (0.95–1.28) 4.31 (4.00–4.63) 2.06 (1.99–2.13)
Colon and Rectum 1.00 0.92 (0.89–0.95) 1.11 (1.06–1.16) 1.02 (0.96–1.07) 0.93 (0.88–0.99) 1.12 (1.10–1.14)
Lung and Bronchus 1.00 0.86 (0.84–0.89) 0.80 (0.76–0.84) 0.93 (0.89–0.98) 0.63 (0.59–0.67) 0.63 (0.62–0.64)
Liver and Intrahepatic Bile Duct 1.00 3.81 (3.61–4.02) 4.05 (3.75–4.37) 1.58 (1.37–1.83) 2.14 (1.90–2.40) 2.86 (2.77–2.95)
Hepatocellular 1.00 4.02 (3.77–4.28) 4.77 (4.39–5.19) 1.65 (1.39–1.96) 2.33 (2.04–2.66) 3.44 (3.32–3.57)
Gallbladder 1.00 3.26 (2.68–3.96) 2.14 (1.50–3.06) 1.99 (1.35–2.95) 3.95 (2.94–5.30) 2.18 (1.92–2.47)
Prostate 1.00 0.90 (0.88–0.91) 0.97 (0.94–1.00) 1.10 (1.07–1.13) 1.13 (1.10–1.16) 1.18 (1.17–1.19)
Bladder 1.00 0.53 (0.50–0.56) 0.70 (0.64–0.75) 0.75 (0.69–0.81) 0.52 (0.47–0.58) 0.69 (0.67–0.71)
Kidney 1.00 1.26 (1.19–1.33) 0.76 (0.68–0.84) 0.88 (0.79–0.99) 1.04 (0.94–1.15) 1.33 (1.29–1.37)
PIR with 95% CI for Females
Hispanic subgroup distribution (%) 18.1 5.8 4.5 8.4 63.2
Stomach 1.00 3.53 (3.31–3.77) 3.65 (3.27–4.08) 1.26 (1.03–1.54) 5.07 (4.66–5.50) 2.80 (2.69–2.92)
Colon and Rectum 1.00 0.84 (0.80–0.87) 1.18 (1.12–1.25) 1.27 (1.20–1.34) 0.94 (0.89–0.99) 1.12 (1.10–1.14)
Lung and Bronchus 1.00 0.62 (0.59–0.64) 0.74 (0.70–0.79) 0.58 (0.53–0.62) 0.49 (0.46–0.52) 0.59 (0.58–0.60)
Female Breast 1.00 0.89 (0.88–0.91) 0.80 (0.77–0.83) 0.93 (0.90–0.97) 0.87 (0.85–0.89) 0.95 (0.94–0.96)
Liver and Intrahepatic Bile Duct 1.00 4.23 (3.92–4.56) 3.31 (2.85–3.84) 2.46 (2.05–2.97) 3.09 (2.70–3.54) 2.51 (2.38–2.64)
Hepatocellular 1.00 4.77 (4.31–5.29) 4.51 (3.76–5.40) 2.52 (1.93–3.28) 3.51 (2.94–4.19) 3.60 (3.38–3.83)
Gallbladder 1.00 4.62 (4.15–5.14) 2.95 (2.36–3.69) 1.36 (0.96–1.92) 6.30 (5.49–7.23) 2.81 (2.61–3.03)
Cervix 1.00 2.76 (2.65–2.87) 2.35 (2.15–2.58) 2.01 (1.77–2.30) 3.02 (2.85–3.19) 1.94 (1.89–1.99)
Bladder 1.00 0.63 (0.57–0.70) 0.76 (0.65–0.88) 0.69 (0.58–0.81) 0.55 (0.47–0.64) 0.75 (0.71–0.78)
Kidney 1.00 1.34 (1.25–1.43) 0.97 (0.85–1.12) 0.91 (0.78–1.07) 0.97 (0.86–1.09) 1.43 (1.38–1.48)
Source: SEER and NPCR areas reported by NAACCR as meeting high quality standards for 1999–2003.
a The data from 38 cancer registries [Alabama, Alaska, California, Colorado, Connecticut, Delaware, District Of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Mary-
land, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Washington,
West Virginia, Wisconsin] were included covering 82% of U.S., 90% of the Hispanic, 81% of NHW and 79% of NHB populations.
b Category includes Other specific Hispanic origin, Spanish/Hispanic/Latino NOS, and NHIA surname match only.
Abbreviations: CI ¼ confidence interval.
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TABLE 11
The Stage Distributionsa of Cases for Selected Common Cancer Sitesb and Age Groups by Race/Ethnicity,c County Poverty,d and Sex in Selected
Arease of the United States, 2001–2003
Hispanic Non-Hispanic White Non-Hispanic Black
County Poverty County Poverty County Poverty
Cancer site <10 10–19 20 All <10 10–19 20 All <10 10–19 20 All
Stagea % % % % % % % % % % % %
Male
Colon and Rectum (Aged 50 and Older)
All (Known) 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Localized 37.3 36.3 36.6 36.5 41.9 41.9 40.0 41.8 34.8 37.7 34.9 36.7
Regional 41.6 44.1 42.4 43.4 40.8 40.3 42.1 40.6 39.4 38.5 39.8 38.9
Distant 21.0 19.6 21.0 20.1 17.3 17.8 17.9 17.6 25.8 23.8 25.3 24.4
Unknown (6.0) (9.8) (10.9) (9.4) (6.8) (7.8) (8.7) (7.4) (7.1) (8.4) (10.6) (8.7)
Lung and Bronchus (Aged 20 and Older)
All (Known) 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Localized 15.7 14.5 15.4 14.9 18.7 19.2 19.3 19.0 15.0 16.0 14.1 15.4
Regional 24.8 24.0 25.4 24.4 28.1 27.8 28.2 28.0 28.5 28.0 27.4 28.0
Distant 59.5 61.5 59.2 60.7 53.1 53.0 52.5 53.0 56.6 56.0 58.5 56.6
Unknown (9.1) (13.3) (16.5) (13.2) (9.7) (11.7) (12.4) (11.0) (9.4) (9.7) (11.5) (10.0)
Prostate (Aged 50 and Older)
All (Known) 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Localized 84.5 83.8 82.6 83.7 86.9 86.1 86.1 86.5 85.2 83.5 84.4 83.9
Regional 10.9 10.8 11.0 10.9 9.6 10.1 9.3 9.8 9.5 9.7 7.8 9.3
Distant 4.6 5.4 6.4 5.4 3.5 3.8 4.6 3.7 5.3 6.8 7.8 6.8
Unknown (6.0) (8.6) (13.9) (9.2) (6.5) (8.7) (9.2) (7.8) (6.4) (8.0) (10.3) (8.2)
Female
Breast (Aged 40 and Older)
All (Known) 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Localized 60.6 58.3 55.7 58.3 66.4 66.2 64.5 66.2 56.5 54.6 54.4 54.9
Regional 35.3 36.6 37.9 36.6 29.3 29.3 30.5 29.4 36.8 37.6 37.1 37.4
Distant 4.1 5.2 6.4 5.2 4.3 4.5 5.0 4.4 6.7 7.8 8.5 7.8
Unknown (3.2) (5.9) (7.6) (5.7) (3.5) (4.4) (5.1) (4.1) (4.6) (5.3) (6.4) (5.4)
Cervix (Aged 20 and Older)
All (Known) 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Localized 55.7 53.5 48.9 53.0 56.7 55.4 57.9 56.1 44.3 47.5 45.1 46.5
Regional 36.7 37.2 41.7 37.9 32.9 34.0 32.4 33.5 42.9 40.8 40.9 41.1
Distant 7.6 9.3 9.4 9.1 10.4 10.6 9.8 10.5 12.8 11.8 14.0 12.4
Unknown (4.7) (6.5) (12.0) (7.2) (6.3) (7.9) (8.0) (7.3) (6.6) (7.8) (10.2) (8.2)
Colon and Rectum (Aged 50 and Older)
All (Known) 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Localized 35.1 39.9 36.2 38.4 39.7 40.5 38.7 40.1 35.6 36.7 35.5 36.3
Regional 46.3 41.7 43.0 42.7 43.3 42.2 43.3 42.7 42.6 41.4 42.4 41.8
Distant 18.5 18.4 20.7 18.8 17.0 17.3 18.0 17.2 21.8 21.9 22.1 22.0
Unknown (6.4) (9.7) (9.9) (9.2) (7.3) (8.3) (8.8) (7.9) (7.1) (8.8) (11.5) (9.1)
Lung and Bronchus (Aged 20 and Older)
All (Known) 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Localized 19.2 19.1 18.2 19.0 22.6 22.4 21.3 22.4 18.1 18.1 16.7 17.8
Regional 25.9 24.9 26.0 25.3 27.1 27.1 27.0 27.1 27.9 27.8 27.5 27.8
Distant 54.9 56.0 55.7 55.7 50.3 50.4 51.7 50.5 54.0 54.1 55.8 54.4
Unknown (9.8) (12.6) (17.0) (12.8) (10.1) (12.6) (13.0) (11.6) (8.9) (10.0) (12.0) (10.3)
Source: SEER and NPCR areas reported by the North American Association of Central Cancer Registries as meeting high quality standards for 1999–2003.
a The 2000 SEER Summary Staging System.
b Common cancers for age groups selected based on available tests for diagnosis in early stages of disease progression. Cases excluded when based on death certificate information only.
c NHIA derived Hispanic origin.
d Percent (%) of county population below poverty in 1999.
e The data from 36 cancer registries [Alabama, Alaska, California, Colorado, Connecticut, Delaware, District Of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Massachusetts,
Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Washington, West Virginia,
Wisconsin, but excludes Hawaii and Maryland data] were included covering 80% of U.S., 89% of the Hispanic, 79% of NHW, and 75% of NHB populations.
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Incidence rates of kidney cancer have steadily
increased for 28 years in both men and women. How-
ever, death rates from kidney cancer stabilized in men
and declined in women over the last decade. Trends
in stage-specific incidence rates of kidney cancer sug-
gest that increasing detection of presymptomatic
tumors by ultrasonography, computer tomography,
and magnetic resonance imaging procedures is af-
fecting the trends. However, it does not fully explain
the steady increases.59 Other factors such as smoking,
obesity, and hypertension may also be contributing.60
Incidence rates of leukemia steadily increased
since 1975 in both men and women, while death rates
declined since 1975 in men and 1980 in women. A
study using SEER data from 1973 to 1998 suggested
that leukemia incidence decreased among persons
aged 65 years and older, but increased among persons
younger than 20 years.61 The trends also varied by sub-
type of leukemia.61 The decline in leukemia death rates
can indicate improvements in leukemia treatment.
Melanoma incidence in women continued the in-
crease begun in 1975, but stabilized in men from 2001
to 2003. The fixed interval trends (1995–2003) increased
in both white and non-Hispanic men and women and
API women. Melanoma case reporting is challenging be-
cause diagnosis and treatment often occur outside the
hospital-based cancer-reporting infrastructure. Although
identification of cases has improved, the number of
cases is most likely still underestimated.39,62,63 Although
long-term increases in melanoma incidence are influ-
enced by early detection and improved case reporting,
increasing trends are not confined to early stage tumors
and may also be influenced by historical changes in sun
exposure.63
The statistics for cervical cancer are remarkable,
in that both incidence and mortality rates have been
decreasing for all race/ethnic groups since 1975.
Although the data for specific race and ethnic groups
are not available back to the 1970s, the fixed-interval
rates since 1995 show that both incidence and death
rates are declining in white, black, API, Hispanic, and
non-Hispanic women. The improvements in screen-
ing have had a measurable impact on this disease.64,65
Despite these accomplishments, disparities in the trends
by socioeconomic strata prevail.66
Cancer in Latinos
This report is based on 90% of the U.S. Latino popula-
tion, the most comprehensive coverage of cancer in-
formation for this large and rapidly growing ethnic
group. Although incidence rates for Latinos of specific
origins could not be calculated, the data on screening
and known cancer risk factors among specific Latino
groups suggest several general points: first, not all His-
panic populations in the U.S. are alike;67 second, data
reported from various studies on Hispanic populations
may not be comparable if the underlying Hispanic
populations do not share the same origins, cultural tra-
ditions, and immigration status;68–72 and third, collec-
tion of specific Hispanic origin needs to be increased in
general population and demographic statistics as well
as in the records of persons diagnosed and dying from
cancer.68,73
The cancer incidence data reported here on 90%
of U.S. Latinos mirror findings of many other studies
on various Latino groups or areas,45,68,71,74–81 with a
few exceptions. Rate estimates (Trapido et al. reported
higher rates of cancers of the oral cavity and thyroid in
white Latinas81 and lower rates of stomach cancer in
white Latinos,80 compared with white non-Hispanic
women and men, respectively), rank order of top can-
cer sites (Trapido et al.79 reported for the U.S. that the
top 5 cancer sites for Latinos were prostate, lung, co-
lon, stomach, and rectum and for Latinas, cancers of
the breast, colon, lung, cervix, and uterine corpus.
Canto and Chu68 found stomach cancer to be in the
top 5 for both genders; we report bladder cancer in
males and NHLs in females in the top 5 and not stom-
ach cancer in either gender) and trends varied (both
Cress et al.75 and Eidson et al.82 reported time trends
for years that primarily preceded the 1995–2003 period
reported in this article). Some differences may be at-
tributed to variation in time periods under study,68,75,79,81,82
the specific geographies and thus varying origins of
the local Hispanic population,67,72 or limited statistical
power to detect differences.71,83
U.S. Latinos have lower rates of several cancers that
are higher in affluent, industrialized countries where to-
bacco use, obesity, and physical inactivity may be more
prevalent. Several cancer sites with higher incidence
rates in Latinos have infectious etiologies: human pap-
illoma virus (HPV) in cervical cancer, Helicobacter
pylori (H. pylori) in stomach cancer,84 and Hepatitis B
virus (HBV) and Hepatitis C virus (HCV) in liver cancer
(and hepatocellular carcinoma).85–88 Explanations vary
by site and may include higher prevalence or different
age patterns of infection in the countries of origin
(HPV), chronic infection (HBV and HCV), poor sani-
tary conditions (H. pylori), or varied availability and
use of preventive measures.89 Further, relative to the
NHW populations, the proportion of new site-specific
cancer cases, in relation to all cancer cases, varied
among 4 Latino groups, suggesting that risks may be
different for Latinos of different origin and that cancer
risks may not be generalizable from one Latino group
to another based on Hispanic ethnicity alone, as found
in a comparison of age-adjusted mortality rates among
foreign-born Latino groups in New York City.67
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Children and Adolescents
The incidence of specific cancers differed substantially
among Latino and non-Latino children and adoles-
cents. Incidence rates for leukemia, retinoblastoma,
and germ-cell tumors were higher among Latinos and
rates for CNS tumors, neuroblastoma, renal tumors,
and epithelial tumors were generally lower. Latino
boys had a higher incidence rate of Hodgkin lym-
phoma than did non-Latino boys while all Latino ado-
lescents had lower incidence rates than did NHW
adolescents. Latino boys and girls had higher inci-
dence rates of germ-cell tumors than did NHW chil-
dren, an observation also seen for Latinos and NHW
female adolescents. These findings are consistent with
those of other studies.90–92
The incidence of ALL is generally high in eco-
nomically developed countries and low in developing
countries; however, the highest rates in the world are
reported in Costa Rica and among Latinos in Los
Angeles,93 although geographic variations in incidence
are unexplained. Variation in possible etiologic factors
for childhood leukemias, such as paternal smoking,
occupational exposure to benzene, household sol-
vents, home use of pesticides, radiation, maternal diet,
child’s diet, infection, and genetic susceptibility have
been investigated with inconsistent results.85,94–97
For Hodgkin lymphoma, incidence is low in chil-
dren and high in adolescents and young adults in
developed countries, while in developing countries,
rates are high in childhood, then low until old age.93
Age-related differences in histological subtypes have
been observed.98 Children with Hodgkin lymphoma are
more likely to be positive for Epstein–Barr virus (EBV)
than are adolescent and young adult patients.99 Hodg-
kin lymphoma among adolescents and young adults
may result from a delayed reaction to a common infec-
tious exposure (not EBV) late in adolescence.100
Higher incidence rates among Latino children and
adolescents, than their NHW counterparts, were also
observed for retinoblastoma, germ-cell tumors, and
osteosarcoma. Incidence rates of retinoblastoma in
Central and South America are somewhat higher than
rates in North America and Europe.93 Approximately
40% of children with retinoblastoma have a heritable
gene mutation. Increased risk for retinoblastoma and
osteosarcoma includes treatment with ionizing radia-
tion or alkylating agents, Paget disease, hereditary reti-
noblastoma, and Li-Fraumeni syndrome. Germ-cell
tumors and osteosarcoma are heterogeneous in histol-
ogy, site, and behavior, and show relatively little varia-
tion internationally.93
Among the cancers that have lower incidence in
Latino children and adolescents, CNS tumors, neuro-
blastoma, and renal tumors have lower incidence
rates in Central and South America than in North
America.93 Many questions are unanswered regarding
cancer etiology in children and adolescents, exposure
differences, and genetic predisposition between Lati-
nos and non-Latinos. The diversity and large numbers
of Latino immigrants to the U.S. provide a unique op-
portunity to study childhood and adolescent cancers.
Cancer Risk Factors
The county poverty rate can be a useful indicator of
the availability and accessibility to health services.
Access to state-of-the-art, quality cancer care is known
to be unequal and to exacerbate existing disparities in
cancer outcomes.101–105 The variation in incidence
rates for cancers of the prostate and breast may be
partly related to different rates of screening for these
diseases in counties with more poverty,106 and the
higher incidence rates of cancers of the liver, stomach,
and cervix may be related to higher infection rates in
populations of counties with more poverty. When
available, examination of small geographic areas, such
as census tracts with greater population homogeneity,
could be useful.28,30,31 For an earlier time period, 1988–
1992 in San Francisco Bay, Krieger and colleagues83
used census block group statistics to measure eco-
nomic environment and found that breast cancer inci-
dence increased with increasing area affluence only for
Latinas, unlike the gradient reported here which was
observed for all race/ethnic groups. Cervical cancer
incidence increased for all women with increasing area
deprivation, as did cancers of the prostate and colorec-
tum in both men and women.83
Unlike county poverty rates, metropolitan dispari-
ties were fairly similar among all 3 race/ethnic popula-
tions, suggesting that shared etiologies, a differential
mix of Hispanic groups in metro/nonmetro areas, or
perhaps, the imprecision of some estimates for Hispa-
nics may be more influential factors. This is in contrast
to a report from Texas, that did not find an urban/rural
gradient, particularly among Latinas;107 however, it
was based on regional data from the early 1980s and a
different classification for metro/nonmetro areas.
Overall, Latino men and women were more likely
to be diagnosed with regional/distant disease than
were NHW men and women, consistent with other
reports.69,76,108–110 Similar to data presented here, re-
search demonstrates that Latina women are under-
screened and the extent of underscreening varies by
specific ethnicity and U.S. region of residence.111–118
Results vary of studies examining reasons for lower
screening rates among Latinas. In New York City and
California, when sociodemographic factors were
controlled, the effect of ethnicity disappeared.111,119
However, Northern California Latinos with no direct
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financial barrier were still less likely than NHW per-
sons to obtain screening for breast, colorectal, and
cervical cancers.120 In New York City, the extent of
acculturation had a positive linear association with
breast cancer screening.113 Among Mexican Latinas
in Texas, socioeconomic status (SES) and acculturation
were not related to screening behaviors.121,122 Zam-
brana et al.118 concluded from their analysis of NHIS
data that access factors and screening history were
more important than language and ethnic factors, as
did Selvin and Brett.123
Talavera et al.124 found, from a survey of Latinos in
8 U.S. cities, that access to a healthcare plan/insurance
predicted digital rectal screening for colorectal and
prostate cancer for Mexican and Central American Lati-
nos and English language use was a predictor for Mexi-
cans and Cubans, but not Puerto Ricans. They posit that
the differences may be associated with the local avail-
ability of Spanish-speaking health practitioners. Among
a rural Hispanic population in Washington, mostly origi-
nating from Mexico, support was mixed for the associa-
tion of SES and cancer screening.125 Compared with
NHW persons, breast and colorectal screening differ-
ences disappeared after controlling for SES, and yet
differences in cervical cancer screening and smoking
behavior persisted.125 In the study area, sliding fee
health services were available for all low income per-
sons and yet, regardless of ethnicity, the authors sug-
gested that access barriers, such as long wait-times at
the clinic, may dissuade persons to avail themselves of
screening.125
Latino Outreach and Community Programs
Health disparities among U.S. populations are a focus
for increased research and interventions. Redes En
Accio´n, the National Latino Cancer Research Network
is in the vanguard of U.S. programs seeking to bridge
cancer disparity issues in Latinos.126,127 As one of the
NCI’s Community Networks Programs, Redes En Accio´n
represents a strong effort to coalesce a broad range of
forces—NCI cancer centers, academic institutions, gov-
ernmental entities, national organizations and founda-
tions, and community-based groups—to address diverse
Latino cancer issues. While scientific endeavor is para-
mount, Redes En Accio´n recognizes that the challenges
cannot be met by research alone. Through collabora-
tion, the initiative applies a translational approach,
establishing pipelines from national entities through
regional and local groups to the public, and confronts
issues through a combined research, professional train-
ing, and public education continuum.127
Accomplishing the mission of these networks relies
on accurate and timely data to elucidate differences in
risk factors, site-specific incidence and mortality, and
stage-specific data, potentially related to differences in
access to timely cancer diagnosis and care. Similar to
other groups, lung cancer is the leading cause of cancer
death among Latinos; hence smoking prevention and
cessation efforts are vital in reducing this and other
tobacco-associated cancers. Important considerations
in developing health interventions, including compre-
hensive cancer control, outreach, and care for Latinos,
are higher incidence of some infection-related cancers
in adults; elevated exposures to environmental risk fac-
tors in Latino living and work places; lower education,
health literacy, and income; limited English proficiency;
reduced use of screening services; poorer access to
health care often due to no insurance; and less informa-
tion available regarding possible genetic predisposi-
tions.70,102,114 Also, this population experiences unique
cultural and language barriers to health services, in
addition to the multitude of institutional, environmen-
tal, logistical, sociodemographic and personal barriers
characteristic of all U.S. minority groups.101,127
The Cancer Prevention and Control Research Net-
work (CPCRN) is a national network of academic, public
health, and community partnerships recently estab-
lished to accelerate the adoption of evidence-based can-
cer prevention and control in communities, particularly
those evaluated by the Community Guide.128 The Net-
work is engaged in research and practice activities that
span the translation continuum from discovery to the
dissemination and adoption of effective interventions.
In particular, the Network engages in large-scale efforts
to reach underserved populations. The Latinos in a
Network for Cancer Control is one of the CPCRN sites
whose purpose is to maintain and further develop a
Cancer Prevention and Control Network for Texas and
surrounding states along the U.S.–Mexico Border. The
network collaborators are broad-based and include a
CDC Prevention Research Center at the University of
Texas School of Public Health, community-based orga-
nizations such as the National Center for Farmworker
Health; health departments, practice settings, Redes En
Accio´n, and the NCI-supported cancer research center
at M.D. Anderson. The Racial and Ethnic Approaches
to Community Health (REACH) initiative is another
important federal initiative that supports community
coalitions in designing, implementing, and evaluating
community driven strategies to eliminate disparities
experienced by Latinos and other minority popula-
tions.129
Several examples of other national networks for
community programs include the National Breast and
Cervical Cancer Early Detection Program.130,131 The
Guide to Community Preventive Services evaluates
research on the effectiveness of community inter-
ventions to reduce cancer risk factors and increase
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screening and makes recommendations about effec-
tive interventions,128 including their effectiveness in
low income and minority populations.
Despite limited progress in recent years, accord-
ing to the 2005 DHHS National Health Disparities
Report, health disparities between Latino and NHW
populations have generally increased.132 The Redes En
Accio´n Latino Cancer Report emphasizes the contin-
ued need to improve access to cancer screening and
care, reduce tobacco use, improve communication of
cancer risk, expand research on cancers linked to
infections and cancer-related survivorship and quality
of life, and enhance efforts to educate, train, and reach
out to Latinos for cancer prevention and control.126
Further, addressing Latino cancer issues requires
research on disseminating effective treatments, edu-
cational programs to promote healthier lifestyles, and
use of screening services; greater access to prompt
and appropriate care; clarification of genetic suscept-
ibilities and genetic–environmental interactions; and
improved cultural competency among all cancer care
givers, including physicians.44,69,111,113,114,118 Public
health interventions that may reduce infection-related
cancers among U.S. Hispanic populations include im-
munization against Hepatitis B and the most common
oncogenic strains of HPV, screening and counseling for
Hepatitis B and C, and screening for cervical cancer.89
In addition, despite the existence of strong cultural
protective factors, cancer-related health disparities
affecting Latinos will continue to worsen if the social
and economic disparities noted earlier are not also
addressed.
Issues in Data Interpretation
The data reflect a substantial proportion of the U.S.
population in general, and each of the race/ethnic
groups in particular. It is an achievement that beginning
with 1995, cancer rates can now be generated by site
and sex for most of the U.S. population stratified by eth-
nicity and 3 major race groups. The cancer incidence
surveillance infrastructure has reached a major bench-
mark: high quality data that can be used for cross-
sectional rates and short-term, fixed interval trends.
Some limitations may influence interpretations of
the data. Direct and even self-identification of ethnicity
is preferred, yet still inconsistent and under-reported
on medical records and death certificates.133–138 Indi-
rect methods to enhance this information have been
employed by cancer registries in the past, but with
great regional variation in definition and applica-
tion.35,139 Efforts are in progress to improve the com-
pleteness of self-identification in medical records, but
until that is achieved, all cancer registries can now use
a standard method to enhance identification through
NHIA v2, a method that enhances direct identification
with indirect measures.35 The agencies involved in this
report are also working to improve the identification of
AI/AN and API cancer cases in cancer registries.
Cancer statistics are commonly reported accord-
ing to the major racial and ethnic populations—white,
black, API, AI/AN, and Hispanic/Latino. As suggested
by statistics for Latinos here and by others,140 broad
racial and ethnic groupings may mask wide variations
in the cancer burden for specific API,141,142 AI/AN,
black, or even white, persons, and by cultural charac-
teristics that define high risk populations such as
urbanicity, economic deprivation (both personal and
area-based), or recent immigration.101,143–145 A PIR,
although not a measure of risk, is the best available
measure to look at data for specific Latino and other
groups when neither annual population estimates nor
specific Latino group identification in medical records
are available to compute age-standardized rates.
We used 2 different statistical methods to describe
cancer trends. A joinpoint model was used to charac-
terize long-term patterns for all races combined. A
simple linear model was used to describe trends for a
fixed time period to facilitate comparisons in cancer
incidence and death rates by race/ethnicity, sex, and
cancer sites. In some circumstances, these approaches
may yield different information, leading to different,
even conflicting, interpretations due to the nature of
trends summarized by the 2 models and to the differ-
ent geographic coverage to which each was applied.
The joinpoint method is more flexible and accurate in
identifying the years in which there were significant
changes in trends. The long-term incidence trends are
based on the SEER data covering 10% of the popula-
tion for 1975–2003 (delay-adjusted), and in geographic
areas that are more urban than the U.S. as a whole.
Fixed-interval incidence trends for 1995–2003 are
based on the data reported to NAACCR from SEER and
NPCR registries, covering about 73% of the population
for 1995–2003 (not delay-adjusted).
A county-based economic measure should not be
used to impute individual economic achievement,
being a function of both social and aggregated indivi-
dual characteristics. Moreover, in large metropolitan
U.S. counties, such as Los Angeles, Cook (Chicago), or
New York (Manhattan), even a single county measure
does not accurately reflect the wide variation of area
economic characteristics within the county. Measures
for smaller areas, such as Census block groups, would
be preferable for inferring social or individual eco-
nomic characteristics.83,105 However, identification of
cancer cases by these small geographic areas is difficult
to obtain in amulti-registry-aggregated data file because
of concerns of patient privacy. Most NAACCR member
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registries are not yet comfortable, even if permitted by
law, to release these small area identifiers. We expect
that when permitted by law, these barriers will be over-
come as both incidence and population estimates
improve (minimizing misinterpretation of small area
statistics) and researchers can assure patient privacy.
The percentage of unknown stage cases varied
from 3% to 17% for different race and ethnicity, can-
cer site, and county poverty categories. The large vari-
ation in the percentage of unknown stage cases may
bias comparisons of stage by race, ethnicity, or county
poverty.
Finally, anecdotal reports that Hispanic immi-
grants return to their country of origin after a cancer
diagnosis would cause an underestimate of deaths and
potentially death rates. Generational changes in this
practice could also impact death trends. Empirically
assessing this phenomenon is difficult without com-
plete follow-up of cancer patients migrating out of the
country and without the ability to link on an individual
level, information on foreign-born status from the U.S.
Census and health, cancer, and death data.
Future Directions
The purpose of this report is to provide an overview
of the most current information on the status of the
cancer burden in the U.S. and to spotlight a cancer
topic of interest. To produce the most comprehensive
report, detailed explanations of any one aspect cov-
ered in the report are not feasible. Only reference to
recent research or suggestions for future directions
can be provided for the reader to gain a greater un-
derstanding. This was the first year that detailed can-
cer risk, early detection, and mortality information
were featured with incidence data for 90% of U.S.
Latinos. Description of cancer risks included not only
traditional demographic variables but also urbanicity
and economic environment. Our results raised many
questions: How do the changing race/ethnic demo-
graphic characteristics of the U.S. affect declining
trends? Can they be attributable, even in part, to rapid
growth in the population of persons of lower cancer
risk, like Latino populations? Or, What is driving the
accelerated increase in trend for thyroid cancer in
women, now that the radiation risk affecting older
cohorts is no longer a common practice? Is there a
new emerging risk or can it be explained by better
medical surveillance of other conditions that lead to
the observed increase? And also, If we improve cancer
care through early diagnosis and tumor staging in
high poverty areas, could we improve cancer progno-
sis and mortality in these areas, thereby eliminating
this inequality? Given the general observation that
adolescents and young adults have not realized com-
parable gains in survival and mortality as have chil-
dren and older adults,7 is there an additional disparity
by race or ethnicity? These and other questions need
to be addressed in special studies.
By 2050, the U.S. population will be older; only half
will be white and the greatest growth will occur among
Latino and Asian populations.146 As these populations
age and grow in size, they may influence the cancer
types, prevention and diagnostic practices, and relative
demand for stage-specific treatments and general
access to timely care that will face this nation. Further,
we expect that health care costs will continue to esca-
late. Awareness of these issues must stimulate action to
eliminate known inequalities before they worsen and
are further exacerbated by the aging of the population
and inflationary health care costs.101,103,104,147–150
The inequalities in cancer risk, incidence, and
prognosis between Latino and non-Latino populations
can be reduced by eliminating exposure to infectious
agents that cause cancer; with acculturation in the
U.S., preventing Latinos from adopting traditionally
avoided high risk cancer behaviors;71,72,74,151–154 in-
creasing use of effective clinical prevention services;
and assuring that every person diagnosed with cancer
has affordable and timely access to state-of-the-art,
quality cancer care.102–104,148 We need the continued
support and leadership of all the organizations colla-
borating on this report and the interest of researchers
and cancer control specialists throughout the country
to focus on continued methodologic and classification
improvements in surveillance approaches and to study
the issues and determine effective intervention meth-
ods for diverse populations.155,156 Truly, the public, as
well, must continue to insist that the highest priority
be maintained to reduce the burden of cancer so that
we all can continue to work effectively toward the
elimination of inequalities in the burden of this disease
among all persons in the U.S.
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